WO2008058118A2 - Preparation of montelukast and its salts - Google Patents

Preparation of montelukast and its salts Download PDF

Info

Publication number
WO2008058118A2
WO2008058118A2 PCT/US2007/083756 US2007083756W WO2008058118A2 WO 2008058118 A2 WO2008058118 A2 WO 2008058118A2 US 2007083756 W US2007083756 W US 2007083756W WO 2008058118 A2 WO2008058118 A2 WO 2008058118A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
afford
compound
montelukast
liters
Prior art date
Application number
PCT/US2007/083756
Other languages
French (fr)
Other versions
WO2008058118A3 (en
Inventor
Pratap Reddy Padi
Satyanarayana Bollikonda
Narsimha Naidu
Debasish Ghosh
Kiran Kumar Venkata Kandirelli
Rajender Reddy Jinna
Ravi Kumar Kasturi
Saravanan Mohanarangam
Original Assignee
Dr. Reddy's Labortories, Ltd.
Dr. Reddy's Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Labortories, Ltd., Dr. Reddy's Laboratories, Inc. filed Critical Dr. Reddy's Labortories, Ltd.
Priority to EP07844907A priority Critical patent/EP2094665A4/en
Publication of WO2008058118A2 publication Critical patent/WO2008058118A2/en
Publication of WO2008058118A3 publication Critical patent/WO2008058118A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/02Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring

Definitions

  • the application relates to a process for the preparation of montelukast and its salts.
  • Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLTi receptor and is useful in the treatment of asthma as well as other conditions mediated by leukotrienes, such as inflammation and allergies.
  • Montelukast is commercially available in the market in products sold under the trademark SINGULAR as chewable tablets.
  • SINGULAR as chewable tablets.
  • Each 10 mg, 4 mg, or 5 mg chewable SINGULAIR tablet respectively contains 10.4 mg, 4.2 mg, and 5.2 mg of montelukast sodium, which is equivalent to 10, 4, and 5 mg of montelukast respectively.
  • U.S. Patent No. 5,565,473 discloses montelukast and its related compounds along with their pharmaceutically acceptable salts. It also provides processes for their preparation. Processes for preparation of montelukast and its intermediates have also been described in U.S. Patent No's. 5,614,632 and 5,523,477, U.S. Patent Application Publication Nos. 2005/0234241 A1 , 2005/0256156 A1 , and 2005/0107612, and International Application Publication Nos. WO 2005/105749, WO 2005/000807, WO 2004/108679, WO2006/021974, and WO 2006/008751.
  • Formula (XII) h) treating the compound of the Formula (XII) with (-) diisopionocamphenyl chloroborane to afford methyl 2-(3- ⁇ 3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl ⁇ -3- hydroxy-propyl)-benzoic acid methyl ester of the Formula (XIII); and
  • Formula (I) the process including: a) reacting a diol intermediate of the Formula (II):
  • a process for the purification of dicyclohexylamine salt of montelukast including: a) providing a solution of dicyclohexylamine salt of montelukast in a combination of an alcoholic solvent and a nitrile solvent; b) cooling the solution thereby causing a solid dicyclohexylamine salt of montelukast to separate therefrom; c) isolating the separated solid.
  • Suitable hydrocarbon solvents which may be used for steps (a), (b), (c), and (i) include, but are not limited to toluene, xylene, n-heptane, cyclohexane and the like or mixtures thereof.
  • the molar equivalents of isophthalaldehyde which may be used for the reaction may range form less than about 1.5 to less than about 2.0 to that of the equivalents of 7- chloroquinalidine of Formula (III).
  • Suitable chlorinated solvents which may be used for the reaction in step (c) include, but are not limited to, dichloromethane, chloroform, carbon tetrachloride, and the like or mixtures thereof.
  • the mole ratio of dimethyl carbonate used in step (d) may range from less than about 3.0 molar equivalents to less than about 2.5 molar equivalents to that of the starting compound of Formula (Vl).
  • steps (a) to (i) may be conducted at temperatures of the range of about -20 0 C to about 200 °C.
  • Suitable solvents which may be used for conducting the reactions of steps (d), (e), (f), (h), and (g) include, but are not limited to aprotic polar solvents such as N, N- dimethylformamide (DMF), dimethylsulfoxide (DMSO), N,N-dimethylacetamide, acetonitrile and the like; ethers such as tetrahydrofuran, 1 ,4-dioxane and the like; halogenated solvents such as dichloromethane, ethylene dichloride and the like; alcohols such as methanol, ethanol and the like; ketonic solvents such as acetone, methylisobutyl ketone and the like; hydrocarbons such as toluene and the like; or mixtures thereof or their combination with water in various proportions without limitation.
  • aprotic polar solvents such as N, N- dimethylformamide (DMF), dimethylsulfoxide (DMSO), N,N-dimethylacetamide
  • the intermediates at each of the stages are isolated and purified by recrystallization or slurry in a suitable solvent.
  • suitable solvents which may be used for recrystallization or slurry of the compound at each stage include, but are not limited to, alcoholic solvents such as methanol, ethanol, propanol, isopropyl alcohol, n-butanol and the like; hydrocarbon solvents such as toluene, xylene, n-hexane, n-heptane, cyclohexane and the like; halogenated solvents such as dichloromethane, chloroform, ethylene dichloride, carbon tetrachloride and the like; and esters such as ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate, tertiary-butyl acetate and the like or mixtures thereof, or their mixtures with water in various proportions.
  • the diol intermediate obtained using the process described above has a purity of more than about 99%, or more than about 99.5% as determined by High Performance Liquid Chromatography (HPLC). It contains less than about 1.0%, or less than about 0.5% of individual process related impurities. More particularly, it contains less than about 0.5%, or less than about 0.1 % of the following potential process related impurities: 2-(2-(3(S)-(3-(2-(7-chloro-2-quinolinyl) ethenyl) phenyl)-3(hydroxypropyl) acetophenone of the Formula (VII):
  • Suitable solvents which may be used for the reaction include, but are not limited to hydrocarbon solvents such as toluene, xylene, n-hexane, n-heptane, cyclohexane and the like; halogenated solvents such as dichloromethane, chloroform, ethylene dichloride, carbon tetrachloride and the like; and esters such as ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate, tertiary-butyl acetate and the like.
  • hydrocarbon solvents such as toluene, xylene, n-hexane, n-heptane, cyclohexane and the like
  • halogenated solvents such as dichloromethane, chloroform, ethylene dichloride, carbon tetrachloride and the like
  • esters such as ethyl acetate,
  • the mole ratio of vinyl magnesium bromide used to the starting compound of Formula (V) may range from about 0.5 to about 2.0, or from about 1 to about 1.5.
  • the mole ratio of methyl 2-iodobenzoate to the starting compound of Formula (V) may range from about 0.8 to about 1.5, or from about 0.8 to 1.5.
  • the condensation reaction with methyl 2-iodobenzoate takes place in the presence of a base.
  • bases which may be used include, but are not limited to methylamine, dimethylamine, triethylamine, ethyl diisopropylamine, butylamine and the like; and inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium methoxide, potassium methoxide and the like.
  • Suitable temperatures for conducting the reaction range from about 10 0 C to about 100 °C.
  • the obtained 2-(3- ⁇ 3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl ⁇ -3-oxo-propyl)- benzoic acid methyl ester of Formula (XII) has a purity of more than about 95%, or more than about 99% by HPLC.
  • Suitable hydrocarbon solvents which may be used for the reaction in step (c) include, but are not limited to toluene, xylene, n-heptane, cyclohexane and the like or mixtures thereof.
  • the molar ratio of base used in step (a) may range from less than about 2.0 to less than about 1.5 molar equivalents to that of the diethyl malonate taken.
  • the pure compound can be collected using fractional distillation of the residue obtained after reaction.
  • Suitable bases which may be used for the reactions in steps (a) and (c) include, but are not limited to alkali metal hydrides such as lithium hydride, sodium hydride and the like; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and the like; carbonates of alkali metals such as sodium carbonate, potassium carbonate and the like; bicarbonates of alkali metals such as sodium bicarbonate, potassium bicarbonate, and the like; ammonia; and mixtures thereof. These bases can be used in the form of solids or in the form of aqueous solutions.
  • Suitable solvents which may be used for the reactions of steps (a), (b), (d), (e), and (f) include, but are not limited to alcoholic solvents such as methanol, ethanol, isopropanol, n-butanol, tertiary-butanol, and the like; ethers such as diethyl ether, dimethyl ether, diisopropyl ether, tetrahydrofuran, 1 ,4 dioxane, and the like; hydrocarbon solvents such as toluene, xylene, and the like; polar aprotic solvents like dimethylformamide, dimethylsulphoxide, diemthylacetamide, and the like; chlorinated solvents like dichloromethane, chloroform, carbon tetrachloride, chlorobenzene and the like; and mixtures of such solvents and water in various proportions.
  • alcoholic solvents such as methanol, ethanol, isopropanol, n
  • the i-(mercaptomethyl) cyclopropane acetonitrile of Formula (XIV) obtained using the process described above has a purity by GC of more than about 95%, or more than about 98%. It contains less than about 1.0 %, or less than about 0.5% of the corresponding impurities like the dinitrile impurity of Formula (XIVa) and 1- (acetylthiomethyl)-cyclopropaneacetonitrile of Formula XX.
  • Formula (XXI) a key intermediate in the synthesis of montelukast, that includes reacting the diol intermediate of the Formula Il with methane sulfonyl chloride in the presence of a base, in a reaction medium which is essentially free of moisture.
  • reaction medium is used herein to refer to the entire liquid phase of the reaction mass, including solvent, if any, and reaction components, but excluding the headspace of the reactor or reaction vessel over the reaction mass.
  • essentially free of moisture is used herein to denote the total water content of the reaction medium (as determined using standard Karl Fischer methodology) that is less than about 0.6 % w/w.
  • the water content of the reaction medium is less than about 0.5% w/w, more preferably, less than about 0.2% w/w.
  • Suitable solvents which may be used for conducting the reaction include, but are not limited to hydrocarbon solvents such as toluene, xylene, n-hexane, n-heptane, cyclohexane and the like; nitrile solvent such as acetonitrile, propionitrile and the like, or mixtures thereof in suitable ratios.
  • Suitable bases which may be used for the reaction include but are not limited to: organic bases such as methylamine, dimethylamine, triethylamine, ethyl diisopropylamine, butylamine and the like; and inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium methoxide, potassium methoxide and the like.
  • the moisture present in the starting diol intermediate of Formula (II) may be removed by performing azeotropic distillation of its solution in a hydrocarbon solvent such as toluene.
  • a combination of a hydrocarbon solvent with a nitrile solvent is used as the solvent medium, more preferably, a combination of toluene and acetonitrile in a ratio of about 2: 8, or about 1 :9 is used for the purpose of this reaction.
  • the moisture content of the individual reactants such as the methanesulfonyl chloride, diisopropyl ethylamine and the solvents is preferably below about 0.2% w/w to ensure that the moisture content of the total reaction medium is minimized, preferably to below about 0.2% w/w.
  • the methods which may be used for the removal of water from the reaction medium include but are not limited to azeotropic distillation, using molecular sieves, using drying agents like anhydrous sulphates of alkali or alkaline earth metals, and distillation in the presence or absence of vacuum.
  • Step (a) involves (i) mesylation of the diol intermediate of Formula (II) with methane sulfonyl chloride in the presence of diisopropyl ethyl amine and a suitable solvent:
  • Suitable solvents which can be used include but are not limited to water immiscible solvents including: hydrocarbon solvents such as toluene, xylene, n-hexane, n-heptane, cyclohexane and the like; halogenated solvents such as dichloromethane, chloroform, ethylene dichloride and the like; and esters such as ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate, tertiary-butyl acetate and the like.
  • hydrocarbon solvents such as toluene, xylene, n-hexane, n-heptane, cyclohexane and the like
  • halogenated solvents such as dichloromethane, chloroform, ethylene dichloride and the like
  • esters such as ethyl acetate, n-propyl acetate, iso
  • Suitable temperatures for conducting the reaction range from about -20 °C to about 50 0 C, or from about -10 °C to about 30 °C.
  • Suitable acids which can be used for hydrolysis include, but are not limited to inorganic acids such as hydrochloric acid hydrobromic acid, and the like; and organic acids such as tartaric acid, succinic acid, acetic acid, citric acid, and the like.
  • Suitable bases which can be used for the purpose include, but are not limited to alkali metal hydrides such as lithium hydride, sodium hydride and the like; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and the like; carbonates of alkali metals such as sodium carbonate, potassium carbonate and the like; bicarbonates of alkali metals such as sodium bicarbonate, potassium bicarbonate, and the like; ammonia; and mixtures thereof.
  • Suitable temperatures for hydrolysis may range from about 10 to about 200 0 C, or from about 30 to about 120 °C.
  • the acid obtained in the reaction medium after hydrolysis may be isolated in crude form or can be further purified by recrystallization or slurry in a suitable solvent before proceeding to the next step.
  • suitable solvents which can be used for isolating and purifying the acid include, but are not limited to alcohols such as methanol, ethanol, isopropyl alcohol, n-propanol, and the like; ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone and the like; hydrocarbons such as toluene, xylene, n- heptane, cyclohexane, and the like; or mixtures thereof or their combinations with water in various proportions.
  • step (b) involves reaction of montelukast acid obtained above with an amine under suitable conditions to afford the corresponding amine salt, which is optionally recrystallized.
  • the salt forming amine preferably has the formula NR1 R2R3, wherein R1 , R2, and R3 is each independently, straight-chain or branched, substituted or unsubstituted, hydrogen, C 1 - C 15 alkyl or hydroxyalkyl, C 3 -Ci 0 single or fused ring, cycloalkyl or aryl.
  • the montelukast acid obtained in step a) can be converted to its amine salt by reaction with the corresponding amine in the presence of a suitable solvent.
  • the organic non-toxic amines which may be used for the preparation of montelukast amine salts include primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, batanine, caffeine, choline, N,N'-dibenzylenediamine, diethylamine, triethylamine, trimethylamine, tripropylamine, and the like.
  • the amine may be added to the reaction mass at temperatures lower than the dissolution temperatures or at the dissolution temperatures. The temperatures for addition of the amine can range from about 0° C to about 60 0 C or more.
  • reaction mass may be maintained further at temperatures lower than the dissolution temperatures such as for example below about 10° C to about 25° C, for a period of time as required for a more complete isolation of the product.
  • temperatures lower than the dissolution temperatures such as for example below about 10° C to about 25° C, for a period of time as required for a more complete isolation of the product.
  • the exact cooling temperature and time required for complete precipitation can be readily determined by a person skilled in the art.
  • small amounts of seeding crystals montelukast amine salt may be added to the reaction mixture.
  • small amounts are about 1 to 20 weight %, more preferably about 5 weight %.
  • Seeding crystals may be added before or, where appropriate, after the step initiating the precipitation.
  • the amine salt may be isolated from the reaction mass using techniques such as filtration by gravity, or by suction, centrifugation, and the like.
  • the crystals so isolated will carry a small proportion of occluded mother liquor. If desired the crystals can be washed on the filter with a solvent.
  • the amine used is tertiary butyl amine giving the corresponding montelukast tertiary butyl amine salt, and the solvent used for its isolation is toluene.
  • the amine used is dicyclohexylamine giving the corresponding montelukast dicyclohexylamine salt and the solvent used for its isolation is acetone, or a combination of acetonitrile and isopropanol.
  • the amine salt obtained can be further purified by recrystallization or slurry in a suitable solvent.
  • suitable solvents which can be used for recrystallization or slurry include, but are not limited to methanol, ethanol, isopropyl alcohol, n-propanol, and the like; ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone and the like; hydrocarbons such as toluene, xylene, n-heptane, cyclohexane, n-hexane and the like; nitriles such as acetonitrile, propionitrile and the like; or mixtures thereof or their combinations with water in various proportions.
  • step (c) involves conversion of the amine salt to pure montelukast acid.
  • the process for obtaining montelukast acid from the amine salt involves breaking of the montelukast amine salt using an acid in a suitable solvent.
  • Suitable acids which can be used for breaking the salt include, but are not limited to inorganic acids such as hydrochloric acid, hydrobromic acid, and the like; and organic acids such as acetic acid, formic acid, propionic acid, citric acid, and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, and the like
  • organic acids such as acetic acid, formic acid, propionic acid, citric acid, and the like.
  • aqueous solutions containing about 5% to 50%, or about 10% to 20%, (w/v) of the corresponding acid or base can be used. Any concentration is useful, which will convert the amine salt to montelukast acid.
  • the salt is taken into an organic solvent and treated with an aqueous solution of an acid to break the amine salt and release the free acid which remains in the organic layer.
  • the montelukast acid thus obtained can be further purified by recrystallization or slurry in a suitable solvent.
  • Suitable solvents which can be used for purifying montelukast acid include but are not limited to: alcohols such as methanol, ethanol, isopropyl alcohol, n-propanol, and the like; ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone and the like; hydrocarbons such as toluene, xylene, n-heptane, cyclohexane, and the like; or mixtures thereof or their combinations with water in various proportions.
  • alcohols such as methanol, ethanol, isopropyl alcohol, n-propanol, and the like
  • ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone and the like
  • hydrocarbons such as toluene, xylene, n-heptane, cyclohexane, and the like; or mixtures thereof or their combinations with water in various proportions
  • a process for the purification of montelukast dicyclohexylamine salt that includes: a) providing a solution of montelukast dicyclohexylamine sat in a combination of an alcoholic and a nitrile solvent; b) optionally treating the solution with activated charcoal; c) crystallizing the solid from the solution; d) recovering the separated solid.
  • Step (a) involves providing a solution of montelukast dicyclohexylamine sat in a combination of an alcoholic and a nitrile solvent.
  • Suitable alcoholic solvents which can be used for suspending montelukast dicyclohexylamine salt include, but are not limited to alcohols such as methanol, ethanol, isopropyl alcohol, n-propanol, and the like; and suitable nitrile solvents which can be used for the purpose include, but are not limited to acetonitrile, propionitrile and the like.
  • the ratio of the alcoholic solvent to the nitrile solvent which can be used for purification ranges from about 1 :3 to about 1 :5.
  • the dissolution temperatures may range from about 20 to 120° C depending on the solvent used for dissolution. Any other temperature is also acceptable as long as the stability of montelukast is not compromised and a clear solution is obtained.
  • the quantity of solvent used for dissolution depends on the solvent and the dissolution temperature adopted.
  • the concentration of montelukast amine in the solution may generally range from about 0.1 to about 10 g/ml in the solvent.
  • Step (b) involves optionally treating the solution with activated charcoal.
  • the solution obtained in step (a) can be optionally treated with activated charcoal to enhance the color of the compound followed by filtration through a medium such as through a flux calcined diatomaceous earth (Hyflow) bed to remove the carbon.
  • a flux calcined diatomaceous earth (Hyflow) bed to remove the carbon.
  • the carbon treatment can be given either at the dissolution temperatures or after cooling the solution to lower temperatures.
  • Step (c) involves crystallizing the solid from the solution.
  • the reaction mass may be maintained further at temperatures lower than the concentration temperatures such as for example below about 10° C to about 25° C, for a period of time as required for a more complete isolation of the product.
  • concentration temperatures such as for example below about 10° C to about 25° C
  • the exact cooling temperature and time required for complete crystallization can be readily determined by a person skilled in the art and will also depend on parameters such as concentration and temperature of the solution or slurry.
  • crystallization may be initiated by methods such as cooling, seeding, partial removal of the solvent from the solution, by adding an anti-solvent to the solution or a combination thereof.
  • Step (d) involves recovering the separated solid.
  • the method by which the solid material is recovered from the final mixture, with or without cooling below the operating temperature can be any of techniques such as filtration by gravity, or by suction, centrifugation, and the like.
  • the crystals so isolated will carry a small proportion of occluded mother liquor. If desired the crystals can be washed on the filter with a solvent.
  • the above described process of the invention can be adapted to form the basis of a continuous crystallization process where the steps (a) to (d) are repeated with the wet material obtained in step (d). When the desired purity is attained at step d), the cycle is stopped.
  • the wet cake obtained in step d) may optionally be further dried. Drying can be suitably carried out in a tray dryer, vacuum oven, air oven, or using a fluidized bed drier, spin flash dryer, flash dryer and the like. The drying can be carried out at temperatures of about 35° C to about 70° C. The drying can be carried out for any desired time periods, times about 1 to 20 hours.
  • Montelukast acid obtained above may be converted into its sodium salt.
  • Suitable solvents which may be used for suspending montelukast acid include, but are not limited to; alcoholic solvents like methanol, ethanol, isopropyl alcohol and the like, ketonic solvents such as acetone, ethylmethyl ketone, methyl isobutyl ketone and the like.
  • Sodium hydroxide can be added to the mixture of montelukast acid in a solvent in the form of an aqueous solution or as a solution in an alcoholic solvent.
  • Isolation of montelukast sodium from the solution can be done by removal of the solvent, which may be carried out suitably using techniques such as evaporation, atmospheric distillation, distillation under vacuum, and the like.
  • Distillation of the solvent may be conducted under vacuum, such as below about 100 mm Hg to below about 600 mm Hg, at elevated temperatures such as about 20° C to about 70° C. Any temperature and vacuum conditions can be used as long as there is no increase in the impurity levels of the product.
  • Suitable techniques which can be used for the solvent removal include, distillation using a rotational evaporator device such as a Buchi Rotavapor, spray drying, agitated thin film drying (“ATFD”), and the like.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising montelukast or its pharmaceutically acceptable salts prepared according to the process of the present invention along with one or more pharmaceutically acceptable carriers, excipients or diluents.
  • compositions montelukast or its pharmaceutically acceptable salts along with one or more pharmaceutically acceptable carriers of this invention may further formulated as: solid oral dosage forms such as, but not limited to, powders, granules, pellets, tablets, and capsules; liquid oral dosage forms such as but not limited to syrups, suspensions, dispersions, and emulsions; and injectable preparations such as but not limited to solutions, dispersions, and freeze dried compositions.
  • Formulations may be in the form of immediate release, delayed release or modified release.
  • immediate release compositions may be conventional, dispersible, chewable, mouth dissolving, or flash melt preparations, and modified release compositions that may comprise hydrophilic or hydrophobic, or combinations of hydrophilic and hydrophobic, release rate controlling substances to form matrix or reservoir or combination of matrix and reservoir systems.
  • the compositions may be prepared by direct blending, dry granulation or wet granulation or by extrusion and spheronization.
  • Compositions may be presented as uncoated, film coated, sugar coated, powder coated, enteric coated or modified release coated.
  • Compositions of the present invention may further comprise one or more pharmaceutically acceptable excipients.
  • compositions that are of use include but are not limited to film formers, plasticizers, colorants, flavoring agents, sweeteners, viscosity enhancers, preservatives, antioxidants and the like.
  • montelukast or its pharmaceutically acceptable salts is a useful active ingredient in the range of 0.5 mg to 50 mg, or 1 mg to 25 mg.
  • the obtained filtrate was combined and about 80% of the total volume was distilled under vacuum.
  • the concentrated solution was cooled to about 5 0 C and stirring for about 1 hour.
  • the separated solid was filtered and dried at about 70 0 C until the loss on drying was about 2% w/w to afford 40.7 kg of the title compound.
  • the obtained filtrate was combined and passed through a 5 ⁇ m filter to make it particle free.
  • the obtained filtrate was distilled completely at about 40 0 C under vacuum to afford a residue.
  • the residue was cooled to about 30 0 C and n-hexane (375 liters) was added followed by stirring for about 2 hours.
  • the separated solid was filtered and washed with n-hexane (75 liters).
  • the solid obtained was dried at about 70 °C until the loss on drying was about 2% w/w to afford 55 kg of the title compound. Purity by HPLC: 93.52%.
  • the wet solid obtained was taken into another reactor containing methanol (850 liters) and stirred for about 2 hours. The solid was filtered and washed with methanol (170 liters). The solid obtained was dried at about 70 0 C till the loss on drying was about 2% w/w to afford 181 kg of the title compound. Purity by HPLC: 89.73%.
  • EXAMPLE 8 PREPARATION OF 2-(3-(3-[2-(7-CHLORO-QUINOLIN ⁇ -YL)-VINYL]- PHENYL) ⁇ -METHOXYCARBONYL-S-OXO-PROPYL)-BENZOIC ACID METHYL ESTER (FORMULA X):
  • the wet solid was taken into another reactor containing methanol (1110 liters) followed by stirring at 30 0 C for about 2 hours.
  • the separated solid was filtered and washed with methanol (225 liters).
  • the solid obtained was dried at about 70 0 C until the loss on drying was about 2% w/w to afford 185 kg of the title compound. Purity by HPLC: 78.5%.
  • Toluene 250 ml was then added to the reaction mass, and the temperature of the reaction mass was raised to 25-35 0 C and stirred for about 30-45 minutes.
  • the organic layer was separated and the aqueous layer was extracted with toluene (150 ml).
  • the combined organic layer was washed with 5 % aqueous sodium bicarbonate solution (250 ml) followed by washing with water (2X400 ml).
  • the organic layer was distilled azeotropically to remove the traces of water until the reaction volume was 400 ml and then cooled to 25-35 0 C.
  • toluene 75 ml was added to the reaction mass and heated to 70-80 0 C to get the clear dissolution. The solution was then cooled to about 25-35 0 C and maintained for about 2 hours. Then the reaction mass was further cooled to 0-5 0 C and stirred for about 4 hours. The separated solid was filtered and washed with chilled toluene (25 ml) and finally washed with hexanes (100 ml). The wet compound was dried at 50-55 0 C under vacuum to afford 45 g of the title compound.
  • EXAMPLE 12 PREPRATION OF 2-(3-(3-[2-(7-CHLORO-QUINOLIN ⁇ -YL)-VINYL]- PHENYL ⁇ -3-HYDROXY-PROPYL)-BENZOIC ACID METHYL ESTER (FORMULA XIII):
  • reaction mixture was decomposed by the addition of ammonia solution (Conc.5-10%) (35 liters) at about -5 0 C followed by stirring at about 30 0 C for about 2 hours.
  • the reaction solution was washed with saturated sodium chloride solution (9 kg sodium chloride dissolved in 45 L of water) (4*45 liters).
  • the aqueous layer with emulsion was filtered through a Nutsche filter and the filtered bed was washed with dichloromethane (45 liters).
  • the organic layer was separated and distilled completely at about 55 0 C under vacuum followed by cooling to about 30 0 C to afford a residue.
  • EXAMPLE 13 PREPARATION OF 1 -(3-[2-(7-CHLORO-QUINOLIN ⁇ -YL)-VINYL]- PHENYL ⁇ -3-[2-(1 -HYDROXY- 1 -METHYL-ETHYL)-PHENYL]-PROPAN-I -OL (FORMULA II):
  • Methyl magnesium chloride (280 liters) was added slowly into the reaction mass over about 6 hours at about -5 °C followed by stirring for about 2 hours. After completion of the reaction, the reaction was decomposed by the addition of sodium bicarbonate solution (80 kg of sodium bicarbonate dissolved in 600 L of water) followed by stirring for about 30 minutes. The organic layer was separated and the aqueous layer was extracted with toluene (60 liters). The combined organic layer was washed with sodium bicarbonate solution followed by washing with water (2> ⁇ 480 liters).
  • the separated organic layer was taken into another reactor equipped with a Dean-Stark type azeotropic apparatus followed by heating to about 100 0 C and the water that separated was collected.
  • Methyl magnesium chloride 140 liters was added slowly at about 0 0 C over about 6 hours followed by stirring for about 1 hour. The temperature was raised to about 15 0 C followed by stirring for about 3 hours.
  • the reaction was decomposed by the addition of sodium bicarbonate solution (80 kg of sodium bicarbonate dissolved in 600 L of water) below 20 0 C followed by stirring for about 30 minutes. The temperature was raised to about 30 0 C followed by stirring for about 2 hours.
  • the organic layer was separated followed by extraction of the aqueous layer with toluene (60 liters).
  • EXAMPLE 16 PREPARATION OF 1 ,1 -CYCLOPROPANEDIIVIETHANOL CYCLOSULFITE (FORMULA XVIII):
  • the obtained organic layer was taken into a clean reactor followed by adding carbon (2.5 kg) and sodium sulfate (5.5 kg). The reaction mixture was stirred at about 30 0 C for about 20 minutes. The reaction mass was filtered through a celite bed and the bed was washed with dichloromethane (25 liters). The resultant filtrate was passed through a micro filter and the solvent distilled completely at about 45 0 C to afford a residue of the title compound.
  • the filtrate obtained was distilled at about 65 0 C under vacuum to afford a residue.
  • the residue obtained was charged into a vacuum distillation reactor and heated slowly to below 100 0 C for collection of the first fraction. Raised the temperature from 100 0 C and collected the second fraction. Again raised the temperature from 120 0 C and the main fraction was collected to afford 26 kg of the title compound. Purity by GC: 82.4%.
  • EXAMPLE 18 PREPARATION OF 1 -(ACETYLTHIOMETHYL)-CYCLOPROPANENE ACETONITRILE (FORMULA XX):
  • reaction mass was then cooled to -10 0 C and triethylamine (47 liters) was added to the reaction mass at about -10 0 C followed by the addition of thioacetic acid (18 liters) at about O 0 C.
  • the reaction mass was maintained at about 0 0 C for about 2 hours and then the temperature was raised to 30 0 C and maintained for 20 hours.
  • water 250 liters was added and the organic layer was separated. The aqueous layer was extracted with toluene (3x150 liters). The combined organic layer was washed with water (3*125 liters). To the obtained organic layer carbon (1.25 kg) was added and maintained for about 30 minutes.
  • the reaction mass was filtered and the filtered cake was washed with toluene (7 liters).
  • the resultant filtrate was passed through a micro filter and distilled under vacuum at about 50 0 C to remove carbon traces and extraneous matter to 80% v/v of the original volume followed by applying high vacuum slowly at about 45 0 C to afford the title compound. Purity by GC: 84.81%.
  • the aqueous layer was taken into a fresh reactor containing toluene (198 liters). Cooled the reaction solution to 0 0 C, and then pH of the reaction mass was adjusted to about 4 with acetic acid (42 liters) at below 5 0 C. The organic layer was separated and the aqueous layer was extracted into toluene (2x132 liters). The combined organic layer was washed with sodium bicarbonate solution (6.6 kg of sodium bicarbonate dissolved in 132 L of water) in two equal lots followed by washing with water (3 ⁇ 132 liters). The separated organic layer was treated with activated carbon (4.95 kg) and maintained for about 30 minutes.
  • the reaction mass was heated to 70-80 0 C and maintained for about 45 minutes (checked for clear dissolution) followed by further cooling to about -15 0 C.
  • Diisopropylethylamine (9.35 kg) with a water content of about 0.02% w/v by KF was added to the residue at about -13 0 C followed by maintaining for about 15 to 20 minutes.
  • Methanesulfonyl chloride (7.48 kg) with a water content of about 0.02% w/v by KF was added dropwise to the reaction mass at -13 0 C followed by maintaining for about 9 hours.
  • the separated solid was filtered and washed with chilled acetonitrile (60 liters) followed by washing with chilled cyclohexane (60 liters) to afford the intermediate mesylate compound.
  • N,N-dimethylformamide 150 liters
  • a water content of about 0.02% w/v by KF and (i-mercaptomethyl-cyclopropyl)-acetonitrile (11.6 kg) were taken into a clean and dry reactor followed by cooling to about -13 °C .
  • the resultant reaction mass was maintained at about -15 °C for about 20 to 30 minutes followed by adding the intermediate mesylated compound under a N 2 atmosphere at about -13 0 C to about -17 0 C, followed by rinsing the reactor walls with N,N-dimethylformamide (30 liters). The reaction mixture was maintained at about -13 0 C for about 60 minutes. After completion of the reaction, the reaction mass was quenched by adding saturated sodium chloride solution (96 kg sodium chloride in 450 L of water) (450 liters) below 0°C, followed by allowing the temperature of the reaction mass to increase to 30 0 C. The reaction mass was extracted with toluene (300 liters) followed by separation of the organic and aqueous layers.
  • the aqueous layer was extracted into toluene (2*180 liters). The combined organic layer was washed with water (4x360 liters). The organic layer was distilled completely at about 55 0 C under a vacuum of about 600 mm/Hg to afford a residue.
  • reaction mass was washed with toluene (4x180 liters). Toluene (300 liters) was then added to the aqueous layer and pH was adjusted to about 6 by the addition of 9 liters of acetic acid. The resultant reaction mass was cooled to about 28 0 C followed by separation of organic and aqueous phases. The aqueous layer was extracted with toluene (2*180 ml). The combined organic layer was washed with water (5*150 liters). The organic layer was distilled completely at about 55 0 C under a vacuum of about 300 mm/Hg. Toluene (30 liters) was charged to the resultant residue and was stirred at about 28 0 C for about 2 hours.
  • the resultant homogenous solution was cooled to about 2 0 C for about 6 hours.
  • the separated solid was filtered and the solid obtained was washed with toluene (15 liters). Dried the solid at about 70 0 C for about 5 hours to afford 20.4 kg of the crude title compound.
  • the obtained crude was taken into a clean and dry reactor containing methanol (70 liters) and heated to reflux.
  • the reaction mixture was maintained under reflux for 20-30 minutes and then cooled to 25-35 0 C.
  • the reaction mass was maintained at 25- 35 0 C for about 6 hours.
  • the reaction mass was further cooled to about 0 to 5 0 C, and maintained for about 5-6 hours.
  • the isolated solid was filtered and washed with chilled methanol (20 liters).
  • the wet solid was taken into another reactor containing methanol (20 liters) and heated to reflux.
  • the reaction mixture was maintained under reflux for about 20 to 30 minutes and then cooled to about 25-35 0 C.
  • reaction mass was maintained at 25 to 35 0 C for about 5-6 hours, and then further cooled to 0 to 5 0 C and , maintained for about 5-6 hours.
  • the isolated solid was filtered and washed with chilled methanol (20 liters) and the wet solid was dried at about 70 0 C for about 4 hours to afford 15 kg of the title compound. Purity by HPLC: 99.0%.
  • the reaction mixture was stirred for about 60 minutes followed by quenching the reaction mass by the addition of 360 ml of saturated sodium chloride solution (360 g sodium chloride in 1000 ml water) over about 30 minutes.
  • the reaction solution was allowed to reach a temperature of about 30 0 C followed by extraction with 900 ml of dichloromethane.
  • Organic and aqueous layers were separated followed by washing the organic layer with 4 ⁇ 480 ml of water. The organic and aqueous layers were separated and the organic layer was distilled completely at about 55°C under vacuum of about 300 mm Hg to afford 29.4 g of the title compound.
  • EXAMPLE 22 PREPARATION OF MONTELUKAST DICYCLOHEXYLAMINE SALT:
  • Montelukast acid (20 g) and acetone (120 ml) were taken into a round bottom flask followed by stirring for about 15 minutes.
  • Dicyclohexylamine (8.1 ml) was added to the above homogenous reaction solution followed by seeding with montelukast dicyclohexylamine salt (0.2 g).
  • the resultant reaction suspension was stirred for about 45 minutes followed by addition of toluene (60 ml).
  • the resultant reaction suspension was stirred for about 8 hours.
  • the separated solid was filtered and washed with toluene (20 ml).
  • the obtained wet solid was charged into a round bottom flask containing toluene (60 ml) and the mass was heated to about 90 0 C.
  • Activated carbon (2 g) was added and maintained for 20-30 minutes.
  • the reaction mass was filtered through a celite bed in the hot condition and the bed was washed with toluene (40 ml).
  • the obtained filtrate was taken into a fresh round bottom flask and maintained for about 16 hours at about 30 0 C.
  • the separated solid was filtered and washed with toluene (20 ml).
  • the solid obtained was dried at about 55 0 C under vacuum to afford 20 g of the title compound. Purity by HPLC: 99.2%.
  • the filtrate was maintained at 25 to 35 0 C for another 2 hours and then filtered.
  • the filtered solid was washed with 100 ml of acetonitrile and dried under suction.
  • the above process of recrystallization was repeated twice with the same quantities of solvents and dichloromethane (500 ml) was added to the final wet solid.
  • the mixture obtained was washed with a solution of acetic acid (72.5 ml) in water (7500 ml) in 5 equal lots.
  • the organic layer was separated and washed with water (1000 ml) in two equal lots.
  • the organic layer was then distilled in a rota vapor flask at about 50 0 C under a vacuum of about 350 mm/Hg to get a crude.
  • Sodium hydroxide pellets (1.69 g) and methanol (125 ml) were taken into a round bottom flask and stirred for about 15 minutes at 25 to 35 0 C.
  • a mixture of montelukast (25 g) in methanol (125 ml) was prepared and the solution of methanolic sodium hydroxide prepared above was added to it and stirred at 25 to 35 C for about 10 minutes.
  • Activated carbon (2.5 g) was added to the solution and stirred for about 10 minutes at the same temperature. The mixture was then filtered over a celite bed and the bed was washed with methanol (50 ml).

Abstract

There is provided a process for the preparation of montelukast of the Formula (I).

Description

PREPARATION OF MONTELUKAST AND ITS SALTS
TECHNICAL FIELD
The application relates to a process for the preparation of montelukast and its salts.
INTRODUCTION
Montelukast is described chemically as [R-(E)]-1-[[[1-[3-[2-(7-chloro-2- quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]-propyl]thio]methyl] cyclopropane acetic acid and can be represented structurally by Formula (I):
Figure imgf000002_0001
Formula (I)
Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLTi receptor and is useful in the treatment of asthma as well as other conditions mediated by leukotrienes, such as inflammation and allergies.
Montelukast is commercially available in the market in products sold under the trademark SINGULAR as chewable tablets. Each 10 mg, 4 mg, or 5 mg chewable SINGULAIR tablet respectively contains 10.4 mg, 4.2 mg, and 5.2 mg of montelukast sodium, which is equivalent to 10, 4, and 5 mg of montelukast respectively.
U.S. Patent No. 5,565,473 discloses montelukast and its related compounds along with their pharmaceutically acceptable salts. It also provides processes for their preparation. Processes for preparation of montelukast and its intermediates have also been described in U.S. Patent No's. 5,614,632 and 5,523,477, U.S. Patent Application Publication Nos. 2005/0234241 A1 , 2005/0256156 A1 , and 2005/0107612, and International Application Publication Nos. WO 2005/105749, WO 2005/000807, WO 2004/108679, WO2006/021974, and WO 2006/008751.
Although many processes have been described in the prior art for the preparation of montelukast and its intermediates, there still remains a need for a process for the preparation of montelukast which is industrially viable.
SUMMARY
In one embodiment, there is provided a process for preparing 1-{3-[2-(7-chloro- quinolin-2-yl)-vinyl]-phenyl}-3-[2-(1 -hydroxy- 1 -methyl-ethyl)-phenyl]-propan-1 -ol of the Formula (II):
Figure imgf000003_0001
Formula (II) which process includes: a) reacting 7-chloroquinalidine of the Formula (III):
Figure imgf000003_0002
Formula (III) with isophthalaldehyde of the Formula (IV):
Figure imgf000003_0003
Formula (IV) in the presence of acetic anhydride, in a hydrocarbon solvent, to afford (3-[2-(7-chloro-quinolin-2-yl)-vinyl]-benzaldehyde of the Formula (V):
Figure imgf000004_0001
Formula (V); b) reacting the compound of the Formula (V) with methyl magnesium chloride in a hydrocarbon solvent to afford 1-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-ethanol of the Formula (Vl):
Figure imgf000004_0002
Formula (Vl) c) treating the compound of Formula (Vl) with manganese dioxide to afford (1-{3-[2- (7-chloro-quinolin-2-yl)-vinyl]-phenyl}-ethanone of the Formula (VII):
Figure imgf000004_0003
Formula (VII) d) treating the compound of the Formula (VII) with dimethylcarbonate in the presence of sodium methoxide to afford 3-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3- oxo-propionic acid methyl ester of the Formula (VIII):
Figure imgf000004_0004
Formula (VIII) e) reacting the compound of the Formula VIII with methyl-2-bromoethyl benzoate of the Formula (IX) :
Figure imgf000005_0001
Formula (IX) in the presence of a base to afford (2-(3-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-2- methoxycarbonyl-3-oxo-propyl)-benzoic acid methyl ester of the Formula (X);
Figure imgf000005_0002
Formula (X) f) converting the compound of Formula (X) to 2-(3-{3-[2-(7-chloro-quinolin-2- yl)vinyl]-phenyl}-2-methoxycarbonyl-3-oxo-propyl)-benzoic acid of the Formula (Xl):
Figure imgf000005_0003
Formula (Xl) g) treating the compound of the Formula (Xl) with methyl iodide in the presence of a base to afford 2-(3-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3-oxo-propyl)-benzoic acid methyl ester of the Formula (XII):
Figure imgf000005_0004
Formula (XII) h) treating the compound of the Formula (XII) with (-) diisopionocamphenyl chloroborane to afford methyl 2-(3-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3- hydroxy-propyl)-benzoic acid methyl ester of the Formula (XIII); and
Figure imgf000006_0001
Formula (XIII) i) reacting the compound of the Formula (XIII) with methyl magnesium chloride in the presence of a hydrocarbon solvent to afford said compound of the Formula (II).
In another embodiment, there is provided a process for preparing 1- (mercaptomethyl) cyclopropane acetonitrile of the Formula (XIV):
Figure imgf000006_0002
Formula (XIV) which process includes: a) reacting diethyl malonate of the Formula (XV):
COOEt
COOEt Formula (XV) with a base in the presence of more than 5 moles of dichloroethane to afford 1 ,1 cyclopropane diester of the Formula (XVI):
COOEt
0< COOEt Formula (XVI) b) reacting the compound of the Formula (XVI) with sodium borohydride to afford
1 ,1 cyclopropanedimethanol of the Formula (XVII):
Figure imgf000006_0003
Formula (XVII) c) reacting the compound of the Formula (XVII) with thionyl chloride in a hydrocarbon solvent to afford 1 ,1-cyclopropanedimethanol cyclic sulfite of the Formula (XVIII):
Figure imgf000007_0001
Formula (XVIII) d) reacting the compound of the Formula (XVIII) with sodium cyanide in the presence of sodium iodide to afford 1-hydroxymethyl-cyclopropaneacetonitrile of the Formula (XIX):
Figure imgf000007_0002
Formula (XIX) e) reacting the compound of the Formula (XIX) with methanesulfonyl chloride in the presence of thioacetic acid to afford 1-(acetylthiomethyl)-cyclopropaneacetonitrile of the Formula (XX):
Figure imgf000007_0003
Formula (XX) and f) reacting the compound of the Formula (XX) with sodium methoxide to afford the compound of the Formula (XIV).
In yet another embodiment, there is provided a process for preparing 2-(2-(3(S)- (3-(2-(7-chloro-2-quinolinyl) ethenyl) phenyl)-3-methane sulfonyloxypropyl) phenyl)-2- propanol of the Formula (XXI):
Figure imgf000007_0004
Formula (XXI) the process including reacting a diol of the Formula (II):
Figure imgf000008_0001
Formula (II) with methane sulfonyl chloride in the presence of a base in a reaction medium that is essentially free of moisture.
In yet another embodiment, there is provided a process for the preparation of montelukast of the Formula (I):
Figure imgf000008_0002
Formula (I) the process including: a) reacting a diol intermediate of the Formula (II):
Figure imgf000008_0003
Formula (II) with methane sulfonyl chloride in the presence of diisopropyl ethyl amine to afford the compound of the Formula (XXI):
Figure imgf000008_0004
Formula (XXI) b) reacting the compound of the Formula (XXI) with 1- (mercaptomethyl)cyclopropane acetonitrile to afford the compound of the formula (XXII):
Figure imgf000009_0001
Formula (XXII); and c) converting said amine salt of into a free acid of montelukast of the Formula (I).
In yet another embodiment, there is provided a process for the purification of dicyclohexylamine salt of montelukast, the process including: a) providing a solution of dicyclohexylamine salt of montelukast in a combination of an alcoholic solvent and a nitrile solvent; b) cooling the solution thereby causing a solid dicyclohexylamine salt of montelukast to separate therefrom; c) isolating the separated solid.
DETAILED DESCRIPTION
As set forth above, in one embodiment, there is provided a process for the preparation of 1 -{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3-[2-(1 -hydroxy-1 -methyl- ethyl)-phenyl]-propan-1-ol (hereinafter referred to as the diol intermediate) of Formula (II):
Figure imgf000009_0002
Formula (II) which is a key intermediate for the synthesis of montelukast. The process is illustrated in Scheme I:
Figure imgf000010_0001
Formula XIII Formula Il
Scheme I
Suitable hydrocarbon solvents which may be used for steps (a), (b), (c), and (i) include, but are not limited to toluene, xylene, n-heptane, cyclohexane and the like or mixtures thereof.
The molar equivalents of isophthalaldehyde which may be used for the reaction may range form less than about 1.5 to less than about 2.0 to that of the equivalents of 7- chloroquinalidine of Formula (III).
Suitable chlorinated solvents which may be used for the reaction in step (c) include, but are not limited to, dichloromethane, chloroform, carbon tetrachloride, and the like or mixtures thereof. The mole ratio of dimethyl carbonate used in step (d) may range from less than about 3.0 molar equivalents to less than about 2.5 molar equivalents to that of the starting compound of Formula (Vl).
The reactions of steps (a) to (i) may be conducted at temperatures of the range of about -20 0C to about 200 °C.
Suitable solvents which may be used for conducting the reactions of steps (d), (e), (f), (h), and (g) include, but are not limited to aprotic polar solvents such as N, N- dimethylformamide (DMF), dimethylsulfoxide (DMSO), N,N-dimethylacetamide, acetonitrile and the like; ethers such as tetrahydrofuran, 1 ,4-dioxane and the like; halogenated solvents such as dichloromethane, ethylene dichloride and the like; alcohols such as methanol, ethanol and the like; ketonic solvents such as acetone, methylisobutyl ketone and the like; hydrocarbons such as toluene and the like; or mixtures thereof or their combination with water in various proportions without limitation.
Suitably, the intermediates at each of the stages are isolated and purified by recrystallization or slurry in a suitable solvent. Suitable solvents which may be used for recrystallization or slurry of the compound at each stage include, but are not limited to, alcoholic solvents such as methanol, ethanol, propanol, isopropyl alcohol, n-butanol and the like; hydrocarbon solvents such as toluene, xylene, n-hexane, n-heptane, cyclohexane and the like; halogenated solvents such as dichloromethane, chloroform, ethylene dichloride, carbon tetrachloride and the like; and esters such as ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate, tertiary-butyl acetate and the like or mixtures thereof, or their mixtures with water in various proportions.
The diol intermediate obtained using the process described above has a purity of more than about 99%, or more than about 99.5% as determined by High Performance Liquid Chromatography (HPLC). It contains less than about 1.0%, or less than about 0.5% of individual process related impurities. More particularly, it contains less than about 0.5%, or less than about 0.1 % of the following potential process related impurities: 2-(2-(3(S)-(3-(2-(7-chloro-2-quinolinyl) ethenyl) phenyl)-3(hydroxypropyl) acetophenone of the Formula (VII):
Figure imgf000012_0001
Formula (VII) methyl-2-(2-(3(S)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-hydroxypropyl) acetophenone of Formula (VIII):
Figure imgf000012_0002
Formula (VIII) and the isomer 2-(2-(3(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3- hydroxypropl)phenyl)-2-propanol of Formula (Ha).
Figure imgf000012_0003
Formula (Ma)
In another embodiment, there is provided an alternate route for the preparation of 2-(3-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3-oxo-propyl)-benzoic acid methyl ester of Formula (XII) by reacting the compound of the Formula (V) with vinyl magnesium bromide followed by condensation with methyl 2-iodobenzoate to give the compound of the Formula XII.
Suitable solvents which may be used for the reaction include, but are not limited to hydrocarbon solvents such as toluene, xylene, n-hexane, n-heptane, cyclohexane and the like; halogenated solvents such as dichloromethane, chloroform, ethylene dichloride, carbon tetrachloride and the like; and esters such as ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate, tertiary-butyl acetate and the like.
The mole ratio of vinyl magnesium bromide used to the starting compound of Formula (V) may range from about 0.5 to about 2.0, or from about 1 to about 1.5.
The mole ratio of methyl 2-iodobenzoate to the starting compound of Formula (V) may range from about 0.8 to about 1.5, or from about 0.8 to 1.5.
Suitably, the condensation reaction with methyl 2-iodobenzoate takes place in the presence of a base. Suitable bases which may be used include, but are not limited to methylamine, dimethylamine, triethylamine, ethyl diisopropylamine, butylamine and the like; and inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium methoxide, potassium methoxide and the like.
Suitable temperatures for conducting the reaction range from about 10 0C to about 100 °C.
The obtained 2-(3-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3-oxo-propyl)- benzoic acid methyl ester of Formula (XII) has a purity of more than about 95%, or more than about 99% by HPLC.
In yet another embodiment, there is provided a process for the preparation of 1- (mercaptomethyl) cyclopropane acetonitrile of the Formula (XIV):
Figure imgf000013_0001
Formula (XIV) another key intermediate in the synthesis of montelukast. The process is illustrated in Scheme II:
Figure imgf000014_0001
.. ,CH2CN ,CH2CN ,. .CH2CN
IX Step e \^>S
CH2SH J^L CX CH2SAc CH2OH
Formula XIV Formula XX Formula XIX
Scheme
Suitable hydrocarbon solvents which may be used for the reaction in step (c) include, but are not limited to toluene, xylene, n-heptane, cyclohexane and the like or mixtures thereof.
The molar ratio of base used in step (a) may range from less than about 2.0 to less than about 1.5 molar equivalents to that of the diethyl malonate taken. The pure compound can be collected using fractional distillation of the residue obtained after reaction.
Suitable bases which may be used for the reactions in steps (a) and (c) include, but are not limited to alkali metal hydrides such as lithium hydride, sodium hydride and the like; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and the like; carbonates of alkali metals such as sodium carbonate, potassium carbonate and the like; bicarbonates of alkali metals such as sodium bicarbonate, potassium bicarbonate, and the like; ammonia; and mixtures thereof. These bases can be used in the form of solids or in the form of aqueous solutions.
Suitable solvents which may be used for the reactions of steps (a), (b), (d), (e), and (f) include, but are not limited to alcoholic solvents such as methanol, ethanol, isopropanol, n-butanol, tertiary-butanol, and the like; ethers such as diethyl ether, dimethyl ether, diisopropyl ether, tetrahydrofuran, 1 ,4 dioxane, and the like; hydrocarbon solvents such as toluene, xylene, and the like; polar aprotic solvents like dimethylformamide, dimethylsulphoxide, diemthylacetamide, and the like; chlorinated solvents like dichloromethane, chloroform, carbon tetrachloride, chlorobenzene and the like; and mixtures of such solvents and water in various proportions.
The i-(mercaptomethyl) cyclopropane acetonitrile of Formula (XIV) obtained using the process described above has a purity by GC of more than about 95%, or more than about 98%. It contains less than about 1.0 %, or less than about 0.5% of the corresponding impurities like the dinitrile impurity of Formula (XIVa) and 1- (acetylthiomethyl)-cyclopropaneacetonitrile of Formula XX.
Figure imgf000015_0001
Formula (XIVa)
In yet another embodiment, there is provided a process for the preparation of 2- (2-(3(S)-(3-(2-(7-chloro-2-quinolinyl) ethenyl) phenyl)-3-methane sulfonyloxypropyl) phenyl)-2-propanol of Formula (XXI):
Figure imgf000015_0002
Formula (XXI) a key intermediate in the synthesis of montelukast, that includes reacting the diol intermediate of the Formula Il with methane sulfonyl chloride in the presence of a base, in a reaction medium which is essentially free of moisture.
The term "reaction medium" is used herein to refer to the entire liquid phase of the reaction mass, including solvent, if any, and reaction components, but excluding the headspace of the reactor or reaction vessel over the reaction mass. The term "essentially free of moisture," is used herein to denote the total water content of the reaction medium (as determined using standard Karl Fischer methodology) that is less than about 0.6 % w/w. Preferably, the water content of the reaction medium is less than about 0.5% w/w, more preferably, less than about 0.2% w/w.
Suitable solvents which may be used for conducting the reaction include, but are not limited to hydrocarbon solvents such as toluene, xylene, n-hexane, n-heptane, cyclohexane and the like; nitrile solvent such as acetonitrile, propionitrile and the like, or mixtures thereof in suitable ratios.
Suitable bases which may be used for the reaction include but are not limited to: organic bases such as methylamine, dimethylamine, triethylamine, ethyl diisopropylamine, butylamine and the like; and inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium methoxide, potassium methoxide and the like.
The moisture present in the starting diol intermediate of Formula (II) may be removed by performing azeotropic distillation of its solution in a hydrocarbon solvent such as toluene.
Suitably, a combination of a hydrocarbon solvent with a nitrile solvent is used as the solvent medium, more preferably, a combination of toluene and acetonitrile in a ratio of about 2: 8, or about 1 :9 is used for the purpose of this reaction.
The moisture content of the individual reactants such as the methanesulfonyl chloride, diisopropyl ethylamine and the solvents is preferably below about 0.2% w/w to ensure that the moisture content of the total reaction medium is minimized, preferably to below about 0.2% w/w.
The methods which may be used for the removal of water from the reaction medium include but are not limited to azeotropic distillation, using molecular sieves, using drying agents like anhydrous sulphates of alkali or alkaline earth metals, and distillation in the presence or absence of vacuum.
Also provided is a process for the preparation of montelukast from the diol intermediate of the Formula (II). The process is illustrated in Scheme III:
Figure imgf000017_0001
Scheme III
Step (a) involves (i) mesylation of the diol intermediate of Formula (II) with methane sulfonyl chloride in the presence of diisopropyl ethyl amine and a suitable solvent:
Figure imgf000017_0002
Formula Il Formula XXI
The formation of the mesylate is followed by (ii) condensation of the mesylated product with i-(mercaptomethyl) cyclopropane acetonitrile of Formula (XIV) to afford the compound of the Formula (XXII):
Figure imgf000018_0001
Formula XXII
Finally, the compound of the Formula (XXII) is (iii) converted into free acid of montelukast by acidic or basic hydrolysis:
Figure imgf000018_0002
Formula XXII
Formula I
Suitable solvents which can be used include but are not limited to water immiscible solvents including: hydrocarbon solvents such as toluene, xylene, n-hexane, n-heptane, cyclohexane and the like; halogenated solvents such as dichloromethane, chloroform, ethylene dichloride and the like; and esters such as ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate, tertiary-butyl acetate and the like.
Suitable temperatures for conducting the reaction range from about -20 °C to about 50 0C, or from about -10 °C to about 30 °C.
Suitable acids which can be used for hydrolysis include, but are not limited to inorganic acids such as hydrochloric acid hydrobromic acid, and the like; and organic acids such as tartaric acid, succinic acid, acetic acid, citric acid, and the like. Suitable bases which can be used for the purpose include, but are not limited to alkali metal hydrides such as lithium hydride, sodium hydride and the like; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and the like; carbonates of alkali metals such as sodium carbonate, potassium carbonate and the like; bicarbonates of alkali metals such as sodium bicarbonate, potassium bicarbonate, and the like; ammonia; and mixtures thereof. Suitable temperatures for hydrolysis may range from about 10 to about 200 0C, or from about 30 to about 120 °C.
The acid obtained in the reaction medium after hydrolysis may be isolated in crude form or can be further purified by recrystallization or slurry in a suitable solvent before proceeding to the next step. Suitable solvents which can be used for isolating and purifying the acid include, but are not limited to alcohols such as methanol, ethanol, isopropyl alcohol, n-propanol, and the like; ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone and the like; hydrocarbons such as toluene, xylene, n- heptane, cyclohexane, and the like; or mixtures thereof or their combinations with water in various proportions.
With reference to the Scheme III, step (b) involves reaction of montelukast acid obtained above with an amine under suitable conditions to afford the corresponding amine salt, which is optionally recrystallized. With reference to Scheme III, the salt forming amine preferably has the formula NR1 R2R3, wherein R1 , R2, and R3 is each independently, straight-chain or branched, substituted or unsubstituted, hydrogen, C1- C15 alkyl or hydroxyalkyl, C3-Ci0 single or fused ring, cycloalkyl or aryl. The montelukast acid obtained in step a) can be converted to its amine salt by reaction with the corresponding amine in the presence of a suitable solvent. The organic non-toxic amines which may be used for the preparation of montelukast amine salts include primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, batanine, caffeine, choline, N,N'-dibenzylenediamine, diethylamine, triethylamine, trimethylamine, tripropylamine, and the like. The amine may be added to the reaction mass at temperatures lower than the dissolution temperatures or at the dissolution temperatures. The temperatures for addition of the amine can range from about 0° C to about 600C or more. After addition of the amine the reaction mass may be maintained further at temperatures lower than the dissolution temperatures such as for example below about 10° C to about 25° C, for a period of time as required for a more complete isolation of the product. The exact cooling temperature and time required for complete precipitation can be readily determined by a person skilled in the art.
Optionally, small amounts of seeding crystals montelukast amine salt may be added to the reaction mixture. Preferably, small amounts are about 1 to 20 weight %, more preferably about 5 weight %. Seeding crystals may be added before or, where appropriate, after the step initiating the precipitation.
The amine salt may be isolated from the reaction mass using techniques such as filtration by gravity, or by suction, centrifugation, and the like. The crystals so isolated will carry a small proportion of occluded mother liquor. If desired the crystals can be washed on the filter with a solvent.
In an embodiment, the amine used is tertiary butyl amine giving the corresponding montelukast tertiary butyl amine salt, and the solvent used for its isolation is toluene.
In another embodiment, the amine used is dicyclohexylamine giving the corresponding montelukast dicyclohexylamine salt and the solvent used for its isolation is acetone, or a combination of acetonitrile and isopropanol.
Optionally, the amine salt obtained can be further purified by recrystallization or slurry in a suitable solvent. Suitable solvents which can be used for recrystallization or slurry include, but are not limited to methanol, ethanol, isopropyl alcohol, n-propanol, and the like; ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone and the like; hydrocarbons such as toluene, xylene, n-heptane, cyclohexane, n-hexane and the like; nitriles such as acetonitrile, propionitrile and the like; or mixtures thereof or their combinations with water in various proportions. With reference to Scheme III, step (c) involves conversion of the amine salt to pure montelukast acid.
The process for obtaining montelukast acid from the amine salt involves breaking of the montelukast amine salt using an acid in a suitable solvent.
Suitable acids which can be used for breaking the salt include, but are not limited to inorganic acids such as hydrochloric acid, hydrobromic acid, and the like; and organic acids such as acetic acid, formic acid, propionic acid, citric acid, and the like. Suitably, aqueous solutions containing about 5% to 50%, or about 10% to 20%, (w/v) of the corresponding acid or base can be used. Any concentration is useful, which will convert the amine salt to montelukast acid.
Suitably, the salt is taken into an organic solvent and treated with an aqueous solution of an acid to break the amine salt and release the free acid which remains in the organic layer. The montelukast acid thus obtained can be further purified by recrystallization or slurry in a suitable solvent. Suitable solvents which can be used for purifying montelukast acid, include but are not limited to: alcohols such as methanol, ethanol, isopropyl alcohol, n-propanol, and the like; ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone and the like; hydrocarbons such as toluene, xylene, n-heptane, cyclohexane, and the like; or mixtures thereof or their combinations with water in various proportions.
In another embodiment, there is provided a process for the purification of montelukast dicyclohexylamine salt that includes: a) providing a solution of montelukast dicyclohexylamine sat in a combination of an alcoholic and a nitrile solvent; b) optionally treating the solution with activated charcoal; c) crystallizing the solid from the solution; d) recovering the separated solid. Step (a) involves providing a solution of montelukast dicyclohexylamine sat in a combination of an alcoholic and a nitrile solvent. Suitable alcoholic solvents which can be used for suspending montelukast dicyclohexylamine salt include, but are not limited to alcohols such as methanol, ethanol, isopropyl alcohol, n-propanol, and the like; and suitable nitrile solvents which can be used for the purpose include, but are not limited to acetonitrile, propionitrile and the like. The ratio of the alcoholic solvent to the nitrile solvent which can be used for purification ranges from about 1 :3 to about 1 :5.
The dissolution temperatures may range from about 20 to 120° C depending on the solvent used for dissolution. Any other temperature is also acceptable as long as the stability of montelukast is not compromised and a clear solution is obtained.
The quantity of solvent used for dissolution depends on the solvent and the dissolution temperature adopted. The concentration of montelukast amine in the solution may generally range from about 0.1 to about 10 g/ml in the solvent.
Step (b) involves optionally treating the solution with activated charcoal. The solution obtained in step (a) can be optionally treated with activated charcoal to enhance the color of the compound followed by filtration through a medium such as through a flux calcined diatomaceous earth (Hyflow) bed to remove the carbon.
The carbon treatment can be given either at the dissolution temperatures or after cooling the solution to lower temperatures.
Step (c) involves crystallizing the solid from the solution. For crystallization to occur, the reaction mass may be maintained further at temperatures lower than the concentration temperatures such as for example below about 10° C to about 25° C, for a period of time as required for a more complete isolation of the product. The exact cooling temperature and time required for complete crystallization can be readily determined by a person skilled in the art and will also depend on parameters such as concentration and temperature of the solution or slurry.
Optionally crystallization may be initiated by methods such as cooling, seeding, partial removal of the solvent from the solution, by adding an anti-solvent to the solution or a combination thereof.
Step (d) involves recovering the separated solid. The method by which the solid material is recovered from the final mixture, with or without cooling below the operating temperature, can be any of techniques such as filtration by gravity, or by suction, centrifugation, and the like. The crystals so isolated will carry a small proportion of occluded mother liquor. If desired the crystals can be washed on the filter with a solvent. In a particular embodiment of the invention the above described process of the invention can be adapted to form the basis of a continuous crystallization process where the steps (a) to (d) are repeated with the wet material obtained in step (d). When the desired purity is attained at step d), the cycle is stopped.
Thus there is established a cycle of operations which can be repeated indefinitely thereby adapting the process of the invention to a continuous process with obvious attendant advantages on the commercial scale.
The wet cake obtained in step d) may optionally be further dried. Drying can be suitably carried out in a tray dryer, vacuum oven, air oven, or using a fluidized bed drier, spin flash dryer, flash dryer and the like. The drying can be carried out at temperatures of about 35° C to about 70° C. The drying can be carried out for any desired time periods, times about 1 to 20 hours.
Montelukast acid obtained above may be converted into its sodium salt. Suitable solvents which may be used for suspending montelukast acid include, but are not limited to; alcoholic solvents like methanol, ethanol, isopropyl alcohol and the like, ketonic solvents such as acetone, ethylmethyl ketone, methyl isobutyl ketone and the like.
Sodium hydroxide can be added to the mixture of montelukast acid in a solvent in the form of an aqueous solution or as a solution in an alcoholic solvent.
Isolation of montelukast sodium from the solution can be done by removal of the solvent, which may be carried out suitably using techniques such as evaporation, atmospheric distillation, distillation under vacuum, and the like.
Distillation of the solvent may be conducted under vacuum, such as below about 100 mm Hg to below about 600 mm Hg, at elevated temperatures such as about 20° C to about 70° C. Any temperature and vacuum conditions can be used as long as there is no increase in the impurity levels of the product.
Suitable techniques which can be used for the solvent removal include, distillation using a rotational evaporator device such as a Buchi Rotavapor, spray drying, agitated thin film drying ("ATFD"), and the like.
In an embodiment, the present invention also provides a pharmaceutical composition comprising montelukast or its pharmaceutically acceptable salts prepared according to the process of the present invention along with one or more pharmaceutically acceptable carriers, excipients or diluents.
The pharmaceutical compositions montelukast or its pharmaceutically acceptable salts along with one or more pharmaceutically acceptable carriers of this invention may further formulated as: solid oral dosage forms such as, but not limited to, powders, granules, pellets, tablets, and capsules; liquid oral dosage forms such as but not limited to syrups, suspensions, dispersions, and emulsions; and injectable preparations such as but not limited to solutions, dispersions, and freeze dried compositions. Formulations may be in the form of immediate release, delayed release or modified release. Further, immediate release compositions may be conventional, dispersible, chewable, mouth dissolving, or flash melt preparations, and modified release compositions that may comprise hydrophilic or hydrophobic, or combinations of hydrophilic and hydrophobic, release rate controlling substances to form matrix or reservoir or combination of matrix and reservoir systems. The compositions may be prepared by direct blending, dry granulation or wet granulation or by extrusion and spheronization. Compositions may be presented as uncoated, film coated, sugar coated, powder coated, enteric coated or modified release coated. Compositions of the present invention may further comprise one or more pharmaceutically acceptable excipients.
Pharmaceutically acceptable excipients that find use in the present invention include, but are not limited to: diluents such as starch, pregelatinized starch, lactose, powdered cellulose, microcrystalline cellulose, dicalcium phosphate, tricalcium phosphate, mannitol, sorbitol, sugar and the like; binders such as acacia, guar gum, tragacanth, gelatin, polyvinyl pyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, pregelatinized starch and the like; disintegrants such as starch, sodium starch glycolate, pregelatinized starch, crospovidone, croscarmellose sodium, colloidal silicon dioxide and the like; lubricants such as stearic acid, magnesium stearate, zinc stearate and the like; glidants such as colloidal silicon dioxide and the like; solubility or wetting enhancers such as anionic or cationic or neutral surfactants; complex forming agents such as various grades of cyclodextrins, resins; release rate controlling agents such as hydroxypropyl cellulose, hydroxymethyl cellulose, hydroxypropyl methylcellulose, ethyl cellulose, methyl cellulose, various grades of methyl methacrylates, waxes and the like.
Other pharmaceutically acceptable excipients that are of use include but are not limited to film formers, plasticizers, colorants, flavoring agents, sweeteners, viscosity enhancers, preservatives, antioxidants and the like.
In the compositions of present invention montelukast or its pharmaceutically acceptable salts is a useful active ingredient in the range of 0.5 mg to 50 mg, or 1 mg to 25 mg.
Certain specific aspects and embodiments of this invention are described in further detail by the examples below, which are provided only for the purpose of illustration and are not intended to limit the scope of the invention in any manner.
EXAMPLE 1 : PREPARATION OF (3-[2-(7-CHLORO-QUINOLIN^-YL)-VINYL]- BENZALDEHYDE (FORMULA V):
7-chloroquinolidine (195 kg), isophthalaldehyde (177 kg), toluene (2000 liters) and acetic anhydride (213 kg) were taken into a reactor and the resultant reaction mixture was heated to about 105 0C, and stirred for about 10 hours. After completion of the reaction, the reaction mass was cooled to about 30 0C followed by charging of n- hexane (800 liters). The reaction solution was stirred for about 2 hours. The separated solid was filtered and the solid was washed with of n-hexane (200 liters) to afford 810 kg of the title compound in a wet form.
290 kg of the above wet title compound was taken into another reactor containing ethyl acetate (1300 liters). The resultant reaction suspension was heated to about 70 0C followed by stirring for about 60 minutes. The reaction solution was filtered through leaf filter and the filter was washed with ethyl acetate (175 liters). The obtained filtrate was distilled to 55% of the original volume and cooled to about 30 0C. The resultant reaction mass was stirred for about 2 hours. The separated solid was filtered and washed with ethyl acetate (90 liters). The solid obtained was dried at about 70 0C till the loss on drying (LOD) comes to below 2% w/w to afford 54 kg of pure title compound. Purity by HPLC: 94.55%.
EXAMPLE 2: PREPARATION OF (3-[2-(7-CHLORO-QUINOLIN^-YL)-VINYL]- BENZALDEHYDE (FORMULA V):
7-chloroquinolidine (100 kg), isophthalaldehyde (90.5 kg), toluene (400 liters) and acetic anhydride (109.5 kg) were taken into a reactor and the resultant reaction mixture was heated to about 106 0C, and stirred for about 12 hours. After completion of the reaction, the reaction mixture was cooled to about 30 0C. Petroleum ether (400 liters) was charged to the reaction mixture and was stirred for about 2 hours. The separated solid was filtered and the solid was washed with petroleum ether (200 liters) to afford 240 kg of the title compound in a wet form.
100 kg of the above wet title compound was taken into another reactor containing ethyl acetate (1700 liters). The resultant reaction suspension was heated to about 75 0C followed by stirring for about 90 minutes. The reaction solution was filtered through leaf filter. The obtained filtrate was charged into the reactor and cooled to about 2 0C. The resultant reaction mass was stirred for about 90 minutes. The separated solid was filtered and washed with ethyl acetate (100 liters). The solid obtained was dried at about 70 0C till the loss on drying (LOD) comes to below 2% w/w to afford 84.8 kg of pure title compound. EXAMPLE 3: PREPARATION OF 1 -(3-[2-(7-CHLORO-QUINOLIN^-YL)-VINYL]- PHENYL}-ETHANOL (FORMULA VI):
(3-[2-(7-chloro-quinolin-2-yl)-vinyl]-benzaldehyde (135 kg) was charged into a clean dry reactor containing toluene (2025 liters). The reaction mixture was cooled to about -5 °C. Methyl magnesium chloride (203 liters) was added slowly at about -5 0C followed by stirring the reaction mass for about 2 hours. A solution of ammonium chloride (108 kg) dissolved in water (270 liters) was added to the reaction mass at about 5 0C followed by stirring for about 2 hours. The separated solid was filtered followed by subjecting to vacuum for about 4 hours. The wet solid was taken into another reactor containing water (675 liters) and stirred for about 2 hours. The solid was filtered and subjected to vacuum for about 2 hours. The obtained solid was dried at about 70 0C until the loss on drying was below 2% w/w to afford 121 kg of the title compound. Purity by HPLC: 91.35%.
EXAMPLE 4: PREPARATION OF 1 -(3-[2-(7-CHLORO-QUINOLIN^-YL)-VINYL]- PHENYLJ-ETHANOL (FORMULA VI)
(3-[2-(7-chloro-quinolin-2-yl)-vinyl]-benzaldehyde (96 kg) was charged into a clean dry reactor containing toluene (1440 liters). The reaction mixture was cooled to about -5 0C. Methyl magnesium chloride (144 liters) was added slowly at about -5 0C followed by stirring the reaction mass for about 2 hours. A solution of ammonium chloride (77 kg) dissolved in water (192 liters) was added to the reaction mass at about 5 0C followed by stirring for about 90 minutes. The separated solid was centrifuged followed by washing with water (96 liters). The wet solid was taken into another reactor containing water (720 liters) and stirred for about 90 minutes. The solid was centrifuged and washed with water (96 liters). The wet-cake was suck dried for 30 minutes. The obtained solid was dried at about 70 0C until the water content was below 5% w/w to afford 77.2 kg of the title compound. EXAMPLE 5: PREPARATION OF 1 -(3-[2-(7-CHLORO-QUINOLIN^-YL)-VINYL]- PHENYLJ-ETHANONE (FORMULA VII):
1-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-ethanol (50 kg) and toluene (750 liters) were taken into a clean and dry reactor. Manganese dioxide (52 kg) was added over about 15 minutes. The reaction mixture was heated to about 92 0C and collected the water (5 liters) from the azeotropic mixture for about 13 hours. On completion of the reaction, reaction mixture was cooled to about 80 0C and manganese dioxide solid was isolated by filtration. The manganese dioxide isolated was placed into a reactor containing toluene (350 liters) followed by heating to about 85 0C. The mixture was stirred for about 1 hour; the solid was filtered off.
The obtained filtrate was combined and about 80% of the total volume was distilled under vacuum. The concentrated solution was cooled to about 5 0C and stirring for about 1 hour. The separated solid was filtered and dried at about 70 0C until the loss on drying was about 2% w/w to afford 40.7 kg of the title compound.
EXAMPLE 6: PREPARATION OF 1 -(3-[2-(7-CHLORO-QUINOLIN^-YL)-VINYL]- PHENYLJ-ETHANONE (FORMULA VII):
1-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl)-ethanol (75 kg) and of dichloromethane (3375 liters) were taken into a clean and dry reactor. The resultant reaction mixture was heated to about 40 °C for clear dissolution followed by cooling to about 300C. Manganese dioxide (187.5 kg) was added slowly over about 2 hours followed by stirring for about 5 hours. The manganese dioxide solid separated from the reaction mass. Wet manganese dioxide solid was isolated by filtration and was placed into a reactor containing dichloromethane (750 liters) followed by stirring for about 2 hours. The solid was filtered and washed with dichloromethane (125 liters).
The obtained filtrate was combined and passed through a 5 μm filter to make it particle free. The obtained filtrate was distilled completely at about 40 0C under vacuum to afford a residue. The residue was cooled to about 30 0C and n-hexane (375 liters) was added followed by stirring for about 2 hours. The separated solid was filtered and washed with n-hexane (75 liters). The solid obtained was dried at about 70 °C until the loss on drying was about 2% w/w to afford 55 kg of the title compound. Purity by HPLC: 93.52%.
EXAMPLE 7: PREPARATION OF 3-(3-[2-(7-CHLORO-QUINOLIN^-YL)-VINYL]- PHENYL}-3-OXO-PROPIONIC ACID METHYL ESTER (FORMULA VIII)
(1-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-ethanone (169.5 kg) and sodium methoxide (63 kg) were taken into a reactor containing 1 ,4-dioxane (508.5 liters). The reaction mixture was stirred at 30 0C for about 30 minutes. 126 liters of dimethyl carbonate was added to it followed by heating to about 80 0C. The resultant reaction mixture was stirred for about 6 hours and then cooled to about 30 0C. After completion of the reaction water (1695 liters) was added and stirred for about 2 hours. The separated solid was filtered and washed with water (170 liters).
The wet solid obtained was taken into another reactor containing methanol (850 liters) and stirred for about 2 hours. The solid was filtered and washed with methanol (170 liters). The solid obtained was dried at about 70 0C till the loss on drying was about 2% w/w to afford 181 kg of the title compound. Purity by HPLC: 89.73%.
EXAMPLE 8: PREPARATION OF 2-(3-(3-[2-(7-CHLORO-QUINOLIN^-YL)-VINYL]- PHENYL)^-METHOXYCARBONYL-S-OXO-PROPYL)-BENZOIC ACID METHYL ESTER (FORMULA X):
3-(3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3-oxo-propionic acid methyl ester (181 kg) and methyl-2-bromomethylbenzoate (136 kg) were taken into a reactor containing N,N-dimethylformamide (725 liters). Potassium carbonate (73.1 kg) was added to it followed by heating to about 55 0C. The resultant reaction mixture was stirred for about 8 hours. After completion of the reaction, the reaction mass was cooled to about 30 0C followed by addition of saturated ammonium acetate solution (ammonium acetate 135.8 kg dissolved in 545 L of water) over about 60 minutes. Water (1085 liters) was added followed by stirring for about 2 hours. The separated solid was filtered and washed with water (1450 liters). The wet solid obtained was taken into a fresh reactor containing methanol (1085 liters) and stirred for about 2 hours. The solid was filtered and washed with methanol (180 liters). The wet solid was dried at about 70 0C until the loss on drying was about 2% w/w to afford 216 kg of the title compound. Purity by HPLC: 92.31 %.
EXAMPLE 9: PREPARATION OF 2-(3-(3-[2-(7-CHLORO-QUINOLIN^-YL)-VINYL]- PHENYL}-3-OXO-PROPYL)-BENZOIC ACID (FORMULA Xl):
2-(3-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-2-methoxycarbonyl-3-oxo- propyl)-benzoic acid methyl ester (222 kg) was taken into a reactor containing glacial acetic acid (1110 liters) and cone, hydrochloric acid (225 liters). The reaction mixture was heated to about 70 0C followed by stirring for about 12 hours. After completion of the reaction, the reaction mass was cooled to about 30 0C and ammonium chloride solution (444 kg of ammonium chloride dissolved in 1110 L of water) was added slowly to the reaction mass followed by stirring for 2 hours. The separated solid was filtered and washed with water (445 liters).
The wet solid was taken into another reactor containing methanol (1110 liters) followed by stirring at 30 0C for about 2 hours. The separated solid was filtered and washed with methanol (225 liters). The solid obtained was dried at about 70 0C until the loss on drying was about 2% w/w to afford 185 kg of the title compound. Purity by HPLC: 78.5%.
EXAMPLE 10: PREPARATION OF 2-(3-(3-[2-(7-CHLORO-QUINOLIN^-YL)-VINYL]- PHENYLJ-S-OXO-PROPYL)-BENZOIC ACID METHYL ESTER (FORMULA XII):
2-(3-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3-oxo-propyl)-benzoic acid (90 kg) was taken into a reactor containing acetone (1125 liters) and potassium carbonate (33.75 kg). The resultant reaction mixture was stirred at about 30 0C for about 30 minutes. Methyl iodide (20.7 liters) was added to it followed by heating slowly to about 55 0C. The resultant reaction mixture was stirred for about 12 hours followed by cooling to about 30 0C. The separated sold was filtered and washed with acetone (90 liters). The filtrate obtained was distilled completely below 60 0C under vacuum to obtain a residue.
The residue obtained was dissolved in chloroform (900 liters) and the chloroform layer was washed with water 92x340 liters). The organic layer was separated and charcoal carbon (4.5 kg) was added to it and stirred at about 30 0C for about 15 minutes. The mixture was filtered through candy and leafy filters followed by washing with chloroform (45 liters). The filtrate obtained was distilled to 70-75% of the original volume followed by cooling to about 30 0C. To the residue, n-hexane (405 liters) was added followed by stirring at about 30 0C for about 2 hours. The separated solid was filtered and washed with 90 liters of n-hexane. The solid obtained was dried at about 70 0C for about 8 hours to afford 61 kg of the title compound. Purity by HPLC: 95.97%.
EXAMPLE 11 : PREPARATION OF 2-(3-(3-[2-(7-CHLORO-QUINOLIN^-YL)-VINYL]- PHENYL}-3-OXO-PROPYL)-BENZOIC ACID METHYL ESTER OF FORMULA XII:
Toluene (500 ml), 3-[2-(7-chloro-quinolin-2-yl)-vinyl] benzaldehyde (50 g) were taken into a round bottom flask and stirred for about 10 minutes. The reaction mass was then cooled to 0 to -10 0C. Then Vinyl Magnesium bromide (1 M solution in THF) (230 ml) was added slowly at about 0 to -100C under nitrogen atmosphere. After the addition was complete, the reaction mass was maintained at 0 to -100C for about 2 hours. After the reaction was completed, the reaction mass was quenched with 10 % aqueous acetic acid solution (300 ml) below 10 0C . Toluene (250 ml) was then added to the reaction mass, and the temperature of the reaction mass was raised to 25-35 0C and stirred for about 30-45 minutes. The organic layer was separated and the aqueous layer was extracted with toluene (150 ml). The combined organic layer was washed with 5 % aqueous sodium bicarbonate solution (250 ml) followed by washing with water (2X400 ml). The organic layer was distilled azeotropically to remove the traces of water until the reaction volume was 400 ml and then cooled to 25-35 0C. Methyl 2-iodo benzoate (22.4 ml), THF (25 ml) and triethylamine (65.1 ml) was added to the residual organic layer. Palladium acetate (0.25 g) was added and the reaction mass was heated to reflux and maintained under reflux for about 24 hrs. After the reaction was completed, the reaction mass was filtered under hot condition and washed the filtered bed with toluene (100 ml). The combined filtrate was washed with water (2 X250 ml) under hot condition (60-70 0C). The toluene layer was Distill off completely under vacuum below 600C. Then toluene (75 ml) was added to the reaction mass and heated to 70-80 0C to get the clear dissolution. The solution was then cooled to about 25-35 0C and maintained for about 2 hours. Then the reaction mass was further cooled to 0-5 0C and stirred for about 4 hours. The separated solid was filtered and washed with chilled toluene (25 ml) and finally washed with hexanes (100 ml). The wet compound was dried at 50-550C under vacuum to afford 45 g of the title compound.
EXAMPLE 12: PREPRATION OF 2-(3-(3-[2-(7-CHLORO-QUINOLIN^-YL)-VINYL]- PHENYL}-3-HYDROXY-PROPYL)-BENZOIC ACID METHYL ESTER (FORMULA XIII):
(-) diisopionocamphenyl chloroborane (81 ml) and dichloromethane (550 liters) were taken into a clean and dry reactor followed by stirring for about 30 minutes. An additional dichloromethane (225 liters) were charged into the reactor followed by cooling to about 0 °C. 2-(3-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3-oxo-propyl)-benzoic acid methyl ester (45 kg) was added slowly over about one hour. The resultant reaction mixture was stirred at about 0 0C for about 8 hours. After completion of the reaction, the reaction mixture was decomposed by the addition of ammonia solution (Conc.5-10%) (35 liters) at about -5 0C followed by stirring at about 30 0C for about 2 hours. The reaction solution was washed with saturated sodium chloride solution (9 kg sodium chloride dissolved in 45 L of water) (4*45 liters). The aqueous layer with emulsion was filtered through a Nutsche filter and the filtered bed was washed with dichloromethane (45 liters). The organic layer was separated and distilled completely at about 55 0C under vacuum followed by cooling to about 30 0C to afford a residue.
The residue obtained was dissolved in methanol (540 liters) followed by stirring at about 30 0C for about 4 hours. The separated gummy solid was filtered and the resultant filtrate was taken into a fresh reactor. Water (135 liters) was added slowly over about 4 hours followed by stirring for about 2 hours then methanol (22.5 liters) and water (22.5 liters) were added. The separated solid was filtered and washed with n- hexane (90 liters) and spin-dried for 3 hours to afford 60 kg of the title compound. EXAMPLE 13: PREPARATION OF 1 -(3-[2-(7-CHLORO-QUINOLIN^-YL)-VINYL]- PHENYL}-3-[2-(1 -HYDROXY- 1 -METHYL-ETHYL)-PHENYL]-PROPAN-I -OL (FORMULA II):
2-(3-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3-hydroxy-propyl)-benzoic acid methyl ester (60 kg) and toluene (960 liters) were taken into a clean and dry reactor equipped with Dean-Stark type azeotropic apparatus. The resultant reaction suspension was heated to about 112 0C followed by stirring for about 2 hours, and simultaneously separated unwanted water was collected in the Dean-Stark apparatus along with solvent from the reaction solution. The resultant reaction mass with a water content < 0.1% w/v by the Karl Fischer ("KF") method was cooled to about -5 0C. Methyl magnesium chloride (280 liters) was added slowly into the reaction mass over about 6 hours at about -5 °C followed by stirring for about 2 hours. After completion of the reaction, the reaction was decomposed by the addition of sodium bicarbonate solution (80 kg of sodium bicarbonate dissolved in 600 L of water) followed by stirring for about 30 minutes. The organic layer was separated and the aqueous layer was extracted with toluene (60 liters). The combined organic layer was washed with sodium bicarbonate solution followed by washing with water (2><480 liters).
The separated organic layer was taken into another reactor equipped with a Dean-Stark type azeotropic apparatus followed by heating to about 100 0C and the water that separated was collected. Methyl magnesium chloride (140 liters) was added slowly at about 0 0C over about 6 hours followed by stirring for about 1 hour. The temperature was raised to about 15 0C followed by stirring for about 3 hours. The reaction was decomposed by the addition of sodium bicarbonate solution (80 kg of sodium bicarbonate dissolved in 600 L of water) below 200C followed by stirring for about 30 minutes. The temperature was raised to about 30 0C followed by stirring for about 2 hours. The organic layer was separated followed by extraction of the aqueous layer with toluene (60 liters). The combined organic layer was washed with sodium bicarbonate solution followed by washing with water (2*480 liters). Organic and aqueous layers were separated and the organic layer was distilled completely below 600C under vacuum to afford a residue. The resultant residue was dissolved in toluene (100 liters) followed by heating to about 60 0C for complete dissolution. The resultant solution was cooled to about 30 0C followed by stirring for about 3 hours. The mass was cooled to about 0 0C and maintained for one hour. The separated solid was filtered and washed with petroleum ether and spin-dried for 30 minutes to afford 43 kg of title compound.
EXAMPLE 14: PREPARATION OF 1 ,1 CYCLOPRANEDIESTER (FORMULA XVI):
1 ,2-dichloroethane (400 liters), diethyl malonate (145 kg), N,N-dimethyl formamide (365 liters), and potassium carbonate (187 kg) were taken into a reactor equipped with a Dean-Stark type azeoptropic apparatus. The reaction mixture was heated to reflux followed by stirring for about 30 hours, simultaneously removing unwanted water that was collected in the Dean Stark apparatus. The reaction mixture was cooled to about 30 0C. The reaction mass was filtered and the filter washed with 510 L of 1 ,2-dichloroethane. The obtained organic layer was washed with water (4*510 L water) and distilled completely under vacuum below 6O0C to obtain a residue. The obtained residue was cooled to 35 0C and high vacuum applied. The reaction mass was heated slowly below 75°C and collect the first fraction. The second fraction was collected by maintaining the temperature at 900C and the third fraction was collected by maintaining the temperature below 120°C for about 5 hours to afford 18.5 kg (2nd and 3rd fractions) of the title compound. Purity by GC: 92.44%.
EXAMPLE 15: PREPARATION OF 1 ,1 CYCLOPROPANEDIMETHANOL (FORMULA XVII):
1 ,1-cyclopropanediester (125 kg), isopropanol (500 liters), and sodium borohydride (117 kg) were taken into a clean and dry reactor, followed by stirring for about 3 hours. Methanol (250 liters) was added slowly at about 25 °C over about 7 hours. The resultant reaction mixture was heated slowly to about 75 0C followed by stirring for about 22 hours. The reaction mass was cooled to about 60 0C then ethyl acetate (500 liters) was charged. Saturated ammonium chloride solution was added to the reaction mass (125 kg of ammonium chloride dissolved in 285 L of water) slowly over about 5 hours at about 30 0C and stirred for about 2 hours. The separated salts were filtered and washed with ethyl acetate (625 liters). The resultant organic layer was distilled completely at about 75 0C under vacuum to afford a residue. The obtained residue was subjected vacuum distillation at a vacuum of about 400-700 mm Hg. The residue was heated slowly and the lower fraction was collected at below 90 0C followed by heating the reaction mass to about 110 0C and main fraction was collected to afford 27.5 liters of title compound. Purity by GC 77.2%
EXAMPLE 16: PREPARATION OF 1 ,1 -CYCLOPROPANEDIIVIETHANOL CYCLOSULFITE (FORMULA XVIII):
1 ,1-cyclopropanedimethanol (23 kg) and triethyl amine (63 liters) were taken into a glass-lined reactor containing dichloromethane (575 liters). The reaction mass was cooled to about -5 0C. Thionyl chloride (17.5 liters) was added slowly at about -5 0C over about 6 hours followed by stirring for about 2 hours at about -5 0C. The reaction mass was decomposed slowly at below 15 0C by the addition of the reaction mass to a disodium hydrogen orthophosphate solution (19.5 kg of disodium hydrogen orthophosphate dissolved in 575 L of water and the pH adjusted to about 7 by the addition of 1 L of orthophosphoric acid). The organic layer was separated and the aqueous layer was extracted with dichloromethane (2*140 liters). The combined organic layer was washed with 5% NaHCO3 solution (7.5 kg dissolved in 155 L of water).
The obtained organic layer was taken into a clean reactor followed by adding carbon (2.5 kg) and sodium sulfate (5.5 kg). The reaction mixture was stirred at about 30 0C for about 20 minutes. The reaction mass was filtered through a celite bed and the bed was washed with dichloromethane (25 liters). The resultant filtrate was passed through a micro filter and the solvent distilled completely at about 45 0C to afford a residue of the title compound.
To the obtained residue, n-hexane (70 liters) was added followed by stirring at about 10 0C for about 1 hour. The separated solid was filtered and washed with precooled n-hexane (25 liters) to afford 23.0 kg of the title compound. Purity by GC: 92.19%.
EXAMPLE 17: PREPARATION OF I-HYDROXYMETHYL-CYCLOPROPANE ACETONITRILE (FORMULA XIX):
I .i-cyclopropanedimethanol cyclic sulfite (60 kg), N,N-dimethylformamide (216 liters), sodium cyanide (24.2 kg), and sodium iodide (12.7 kg) were taken into a clean and dry reactor. The resultant reaction mass was heated slowly to about 100 0C followed by stirring for about 10 hours. The reaction mass was cooled to about 70 0C followed by quenching the reaction mass by the addition of water (11.2 liters) followed by toluene (640 liters). The reaction suspension was stirred at about 45 0C for about 30 minutes. The reaction mass was cooled to about 30 0C and filtered through a celite bed and the bed was washed with toluene (182 liters). The filtrate obtained was distilled at about 65 0C under vacuum to afford a residue. The residue obtained was charged into a vacuum distillation reactor and heated slowly to below 100 0C for collection of the first fraction. Raised the temperature from 1000C and collected the second fraction. Again raised the temperature from 120 0C and the main fraction was collected to afford 26 kg of the title compound. Purity by GC: 82.4%.
EXAMPLE 18: PREPARATION OF 1 -(ACETYLTHIOMETHYL)-CYCLOPROPANENE ACETONITRILE (FORMULA XX):
1-hydroxymethyl-cyclopropaneacetonitrile (25 kg), toluene (100 liters), and N1N- dimethylformamide (50 liters) were taken into a clean and dry reactor. Triethylamine (36 liters) was added to it followed by stirring for about 30 minutes. The reaction mass was cooled to about -5 0C and slowly methane sulfonyl chloride (18.3 liters) was added to the reaction mass at about -5 0C over about 3 hours, and then stirred for about 2 hours at about 0 °C. The reaction mass was then cooled to -10 0C and triethylamine (47 liters) was added to the reaction mass at about -10 0C followed by the addition of thioacetic acid (18 liters) at about O0C. The reaction mass was maintained at about 00C for about 2 hours and then the temperature was raised to 30 0C and maintained for 20 hours. After the reaction was completed, water (250 liters) was added and the organic layer was separated. The aqueous layer was extracted with toluene (3x150 liters). The combined organic layer was washed with water (3*125 liters). To the obtained organic layer carbon (1.25 kg) was added and maintained for about 30 minutes. The reaction mass was filtered and the filtered cake was washed with toluene (7 liters). The resultant filtrate was passed through a micro filter and distilled under vacuum at about 50 0C to remove carbon traces and extraneous matter to 80% v/v of the original volume followed by applying high vacuum slowly at about 45 0C to afford the title compound. Purity by GC: 84.81%.
EXAMPLE 19: PREPARATION OF (I-MERCAPTOMETHYL-CYCLOPROPYL)- ACETONITRILE (FORMULA XIV):
1-(acetylthiomethyl)-cyclopropaneneacetonitrile (33 kg) and methanol (82 liters) were taken into a reactor and cooled to 10 0C. Sodium methoxide solution of concentration of about 20% (58.3 kg) was added slowly into the reaction mass at about 10 0C followed by addition of methanol (42 liters). The reaction mass was maintained at 10 0C for about 3 hours and decomposed slowly by addition of water (330 liters). N- heptane (165 liters) was then added followed by stirring for about 15 minutes at 30 0C. Separated the layers and washed the aqueous layer with 4x165 L of n-heptane. The aqueous layer was taken into a fresh reactor containing toluene (198 liters). Cooled the reaction solution to 0 0C, and then pH of the reaction mass was adjusted to about 4 with acetic acid (42 liters) at below 5 0C. The organic layer was separated and the aqueous layer was extracted into toluene (2x132 liters). The combined organic layer was washed with sodium bicarbonate solution (6.6 kg of sodium bicarbonate dissolved in 132 L of water) in two equal lots followed by washing with water (3χ132 liters). The separated organic layer was treated with activated carbon (4.95 kg) and maintained for about 30 minutes. Filtered the reaction mass through a leaf filter and washed the cake with toluene (66 liters). The reaction solution was distilled off completely under vacuum to 80% of the original volume. The obtained residue was cooled to about 30 °C and charged into an agitated thin film evaporator followed by heating to 550C under a vacuum of 700 mmHg. The obtained crude was cooled to 30 0C to obtain 18.4 liters of title compound. The obtained title compound was stored at below 5 0C under a nitrogen atmosphere in a dry condition. Purity by GC: 84.76%.
EXAMPLE 20: PREPARATION OF MONTELUKAST ACID (FORMULA I):
2-(2-(3(S)-(3-(2-(7-chloro-2-quinolinyl) ethenyl) phenyl)-3-hydroxypropyl) phenyl)- 2-propanol (30 kg) and toluene (150 liters) were taken into a clean and dry reactor. The resultant reaction mass was heated to reflux. 120 liters of toluene was distilled off atmospherically from the reaction mass. (The resultant residue had a water content of 0.1 % w/v by the Karl Fischer ("KF") method). The reaction mass was cooled to about 60 °C and acetonitrile (276 liters) with a water content of about 0.03% w/v by KF was added. The reaction mass was heated to 70-80 0C and maintained for about 45 minutes (checked for clear dissolution) followed by further cooling to about -15 0C. Diisopropylethylamine (9.35 kg) with a water content of about 0.02% w/v by KF was added to the residue at about -13 0C followed by maintaining for about 15 to 20 minutes. Methanesulfonyl chloride (7.48 kg) with a water content of about 0.02% w/v by KF was added dropwise to the reaction mass at -13 0C followed by maintaining for about 9 hours. The separated solid was filtered and washed with chilled acetonitrile (60 liters) followed by washing with chilled cyclohexane (60 liters) to afford the intermediate mesylate compound.
N,N-dimethylformamide (150 liters) with a water content of about 0.02% w/v by KF and (i-mercaptomethyl-cyclopropyl)-acetonitrile (11.6 kg) were taken into a clean and dry reactor followed by cooling to about -13 °C . N-butyllithium in n-hexane (15% w/v) (6.6 kg) was added dropwise to the above reaction mixture at about -17 0C under N2 atmosphere. The resultant reaction mass was maintained at about -15 °C for about 20 to 30 minutes followed by adding the intermediate mesylated compound under a N2 atmosphere at about -13 0C to about -17 0C, followed by rinsing the reactor walls with N,N-dimethylformamide (30 liters). The reaction mixture was maintained at about -13 0C for about 60 minutes. After completion of the reaction, the reaction mass was quenched by adding saturated sodium chloride solution (96 kg sodium chloride in 450 L of water) (450 liters) below 0°C, followed by allowing the temperature of the reaction mass to increase to 30 0C. The reaction mass was extracted with toluene (300 liters) followed by separation of the organic and aqueous layers. The aqueous layer was extracted into toluene (2*180 liters). The combined organic layer was washed with water (4x360 liters). The organic layer was distilled completely at about 55 0C under a vacuum of about 600 mm/Hg to afford a residue.
The above obtained residue and caustic lye (40% NaOH) (120 liters) were taken into a clean and dry reactor equipped with a Dean-Stark type azeotropic apparatus. Heated the reaction mass to about 111 0C and removed toluene from the reaction mass. The resultant reaction mass was maintained at 125 to 130 0C for about 20 hours. After completion of the reaction, the reaction mass was cooled to about 90°C and the caustic lye layer was decanted. Preheated water (to 9O0C) (810 liters) were added and the mixture maintained for about 1 hour for a homogenous solution. pH of resultant solution was adjusted to about 11 by the addition of glacial acetic acid (30 liters) under stirring. The reaction mass was washed with toluene (4x180 liters). Toluene (300 liters) was then added to the aqueous layer and pH was adjusted to about 6 by the addition of 9 liters of acetic acid. The resultant reaction mass was cooled to about 28 0C followed by separation of organic and aqueous phases. The aqueous layer was extracted with toluene (2*180 ml). The combined organic layer was washed with water (5*150 liters). The organic layer was distilled completely at about 55 0C under a vacuum of about 300 mm/Hg. Toluene (30 liters) was charged to the resultant residue and was stirred at about 28 0C for about 2 hours. The resultant homogenous solution was cooled to about 2 0C for about 6 hours. The separated solid was filtered and the solid obtained was washed with toluene (15 liters). Dried the solid at about 70 0C for about 5 hours to afford 20.4 kg of the crude title compound.
The obtained crude was taken into a clean and dry reactor containing methanol (70 liters) and heated to reflux. The reaction mixture was maintained under reflux for 20-30 minutes and then cooled to 25-35 0C. The reaction mass was maintained at 25- 35 0C for about 6 hours. The reaction mass was further cooled to about 0 to 5 0C, and maintained for about 5-6 hours. The isolated solid was filtered and washed with chilled methanol (20 liters). The wet solid was taken into another reactor containing methanol (20 liters) and heated to reflux. The reaction mixture was maintained under reflux for about 20 to 30 minutes and then cooled to about 25-35 0C. The reaction mass was maintained at 25 to 35 0C for about 5-6 hours, and then further cooled to 0 to 5 0C and , maintained for about 5-6 hours. The isolated solid was filtered and washed with chilled methanol (20 liters) and the wet solid was dried at about 70 0C for about 4 hours to afford 15 kg of the title compound. Purity by HPLC: 99.0%.
EXAMPLE 21 : PREPARATION OF MONTELUKAST ACID (FORMULA I):
30 g of 2-(2-(3(S)-(3-(2-(7-chloro-2-quinolinyl) ethenyl) phenyl)-3-hydroxypropyl) phenyl)-2-propanol of Formula Il and 300 ml of toluene were charged into a round bottom flask equipped with a Dean-Stark type azeotropic apparatus. The resultant suspension was heated to about 112°C followed by stirring for about 30 minutes, simultaneously removing unwanted water collected in the Dean-Stark apparatus along with the solvent from the reaction solution. Resultant residue was cooled to about 5O0C and 550 ml of acetonitrile was charged to the residue followed by further cooling to - 15°C. 27.5 ml of diisopropylethylamine was charged to the residue followed by stirring for about 30 minutes. 10.1 ml of methanesulfonyl chloride was added dropwise over about 30 minutes followed by stirring for about 9 hours. Separated solid was filtered and the solid was washed with 120 ml of acetonitrile followed by allowing the temperature to rise to about 5°C. Solid was washed with 120 ml of cyclohexane afford a crude mesylated compound of Formula II.
19.2 g of (i-Mercaptomethyl-cyclopropyl)-acetic acid and 900 ml of tetrahydrofuran (THF) were charged into a clean and dry 4 neck round bottom flask followed by cooling to about -15°C. 200 ml of n-butyl lithium in n-hexane (15% w/v in n- hexane) was added dropwise over about 30 minutes under a N2 atmosphere. The reaction mass was stirred at -15°C for about 30 minutes, followed by charging of the above obtained mesylated compound of Formula Il under a N2 atmosphere. The reaction mixture was stirred for about 60 minutes followed by quenching the reaction mass by the addition of 360 ml of saturated sodium chloride solution (360 g sodium chloride in 1000 ml water) over about 30 minutes. The reaction solution was allowed to reach a temperature of about 30 0C followed by extraction with 900 ml of dichloromethane. Organic and aqueous layers were separated followed by washing the organic layer with 4^480 ml of water. The organic and aqueous layers were separated and the organic layer was distilled completely at about 55°C under vacuum of about 300 mm Hg to afford 29.4 g of the title compound.
EXAMPLE 22: PREPARATION OF MONTELUKAST DICYCLOHEXYLAMINE SALT:
Montelukast acid (20 g) and acetone (120 ml) were taken into a round bottom flask followed by stirring for about 15 minutes. Dicyclohexylamine (8.1 ml) was added to the above homogenous reaction solution followed by seeding with montelukast dicyclohexylamine salt (0.2 g). The resultant reaction suspension was stirred for about 45 minutes followed by addition of toluene (60 ml). The resultant reaction suspension was stirred for about 8 hours. The separated solid was filtered and washed with toluene (20 ml).
The obtained wet solid was charged into a round bottom flask containing toluene (60 ml) and the mass was heated to about 90 0C. Activated carbon (2 g) was added and maintained for 20-30 minutes. The reaction mass was filtered through a celite bed in the hot condition and the bed was washed with toluene (40 ml). The obtained filtrate was taken into a fresh round bottom flask and maintained for about 16 hours at about 30 0C. The separated solid was filtered and washed with toluene (20 ml). The solid obtained was dried at about 55 0C under vacuum to afford 20 g of the title compound. Purity by HPLC: 99.2%.
EXAMPLE 23: PREPARATION OF MONTELUKAST PURE ACID (FORMULA I):
Montelukast dicyclohexylamine salt (30 g) and ethyl acetate (300 ml) were taken into round bottom flask and started stirring. A solution of acetic acid (3.4 ml) in water (150 ml) was prepared and added to the above mixture followed by stirring for about 10 minutes. The organic layer was separated and washed with water (4*150 ml). The organic layer was then distilled at about 65 0C completely under vacuum to afford a residue. To the residue, ethyl acetate (90 ml) was added followed by distillation of the solvent completely to afford a foamy solid of the title compound. Methanol (22.5 ml) was added to the foamy solid followed by cooling to about 5 0C. The resultant reaction suspension was stirred at about 0 0C for about 4 hours. The separated solid was filtered and washed with methanol (7.5 ml). The solid obtained was dried at about 60 0C for about 3 hours to afford 7.4 g of pure title compound. Purity by HPLC: 99.28%.
EXAMPLE 24: PREPARATION OF MONTELUKAST PURE ACID (FORMULA I):
Montelukast (50 g), isopropyl alcohol (150 ml) acetonitrile (375ml), and DCHA salt (20.4 ml) were taken into a round bottom flask and stirred for about 5 minutes. The mixture was heated to about 75 0C and checked for clear dissolution. Carbon (5 g) was added to the solution and stirred for another 30 minutes. The reaction mass was filtered over a celite bed under hot condition and the celite bed was washed wit a mixture of isopropyl alcohol and acetonitrile in a ratio of 1 :3 (100 ml). The combined filtrate was taken into another round bottom flask and allowed to cool to 25 to 35 0C under stirring. The filtrate was maintained at 25 to 35 0C for another 2 hours and then filtered. The filtered solid was washed with 100 ml of acetonitrile and dried under suction. The above process of recrystallization was repeated twice with the same quantities of solvents and dichloromethane (500 ml) was added to the final wet solid. The mixture obtained was washed with a solution of acetic acid (72.5 ml) in water (7500 ml) in 5 equal lots. The organic layer was separated and washed with water (1000 ml) in two equal lots. The organic layer was then distilled in a rota vapor flask at about 50 0C under a vacuum of about 350 mm/Hg to get a crude. To the crude obtained, methanol (150 ml) was added and again distilled out completely. The obtained residue was taken in methanol (75 ml) and stirred at about 25 to 35 0C for about 4 hours, and then cooled to about 0 to 5 0C and maintained for about 5 hours. The separated solid was filtered and washed with methanol (25 ml). The wet compound was then dried at about 50 0C for about 6 hours to yield 31 g of the title compound. Purity By HPLC: 99.69%. EXAMPLE 25: PREPARATION OF MONTELUKAST SODIUM (FORMULA I)
Sodium hydroxide pellets (1.69 g) and methanol (125 ml) were taken into a round bottom flask and stirred for about 15 minutes at 25 to 35 0C. A mixture of montelukast (25 g) in methanol (125 ml) was prepared and the solution of methanolic sodium hydroxide prepared above was added to it and stirred at 25 to 35 C for about 10 minutes. Activated carbon (2.5 g) was added to the solution and stirred for about 10 minutes at the same temperature. The mixture was then filtered over a celite bed and the bed was washed with methanol (50 ml). The combined filtrate was distilled under a vacuum of about 650 mm/Hg at a temperature of about 50 0C and the obtained solid was dried at about 70 °C for 7 hours to yield 24.5 g of the title compound. Purity By HPLC: 99.7% Chiral Purity: 99.9% Residual Solvents: Methanol: 545 ppm, All other solvents: Below LOD.

Claims

We claim:
1. A process for preparing 1-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3-[2-(1-hydroxy-
1-methyl-ethyl)-phenyl]-propan-1-ol of Formula II:
Figure imgf000045_0001
(II) said process comprising: a) reacting 7-chloroquinalidine of the Formula
Figure imgf000045_0002
(III) with isophthalaldehyde of the Formula IV:
Figure imgf000045_0003
(IV)
in the presence of acetic anhydride, in a hydrocarbon solvent, to afford 3-[2-(7-chloro- quinolin-2-yl)-vinyl]-benzaldehyde of the Formula V:
Figure imgf000045_0004
(V); b) reacting the compound of the Formula V with methyl magnesium chloride in a hydrocarbon solvent to afford 1-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-ethanol of the Formula Vl:,
Figure imgf000046_0001
(Vl) c) treating the compound of Formula Vl with manganese dioxide to afford (1-{3-[2- (7-chloro-quinolin-2-yl)-vinyl]-phenyl}-ethanone of the Formula VII:
Figure imgf000046_0002
(VII) d) treating the compound of the Formula VII with dimethylcarbonate in the presence of sodium methoxide to afford 3-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3-oxo- propionic acid methyl ester of the Formula VIII:
Figure imgf000046_0003
(VIM) e) reacting the compound of the Formula VIII with methyl-2-bromoethyl benzoate of the Formula IX :
Figure imgf000046_0004
(IX) in the presence of a base to afford (2-(3-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-2- methoxycarbonyl-3-oxo-propyl)-benzoic acid methyl ester of the Formula X;
Figure imgf000047_0001
(X) f) converting the compound of the Formula X to 2-(3-{3-[2-(7-chloro-quinolin-2- yl)vinyl]-phenyl}-2-methoxycarbonyl-3-oxo-propyl)-benzoic acid of the Formula Xl:
Figure imgf000047_0002
(Xl) g) treating the compound of the Formula Xl with methyl iodide in the presence of a base to afford 2-(3-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3-oxo-propyl)-benzoic acid methyl ester of the Formula XII:
Figure imgf000047_0003
(XII) h) treating the compound of the Formula XII with (-) diisopionocamphenyl chloroborane to afford methyl 2-(3-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3- hydroxy-propyl)-benzoic acid methyl ester of the Formula XIII; and
Figure imgf000047_0004
Formula XIII i) reacting the compound of the Formula XIII with methyl magnesium chloride in the presence of a hydrocarbon solvent to afford said compound of the formula (II).
2. The process of claim 1 , wherein said hydrocarbon solvent of step b) is toluene.
3. The process of claim 1 , wherein said step c) is conducted in a chlorinated solvent.
4. The process of claim 3, wherein said chlorinated solvent is dichloromethane.
5. The process of claim 1 , further comprising purifying said product of step g) by precipitation from a chloroform/n-hexane mixture.
6. A process for preparing i-(mercaptomethyl) cyclopropane acetonitrile of the Formula XIV:
Figure imgf000048_0001
(XIV) said process comprising: a) reacting diethyl malonate of the Formula XV:
COOEt
COOEt
(XV) with a base in the presence of more than 5 moles of dichloroethane to afford 1 ,1 cyclopropane diester of the Formula XVI:
COOEt
COOEt f (XVI) b) reacting the compound of the Formula XVI with sodium borohydride to afford 1 ,1 cyclopropanedimethanol of the Formula XVII:
Figure imgf000048_0002
(XVII) c) reacting the compound of the Formula XVII with thionyl chloride in a hydrocarbon solvent to afford 1 ,1 -cyclopropanedimethanol cyclic sulfite of the Formula XVIII:
Figure imgf000049_0001
(XVIII) d) reacting the compound of the Formula XVIII with sodium cyanide in the presence of sodium iodide to afford 1-hydroxymethyl-cyclopropaneacetonitrile of the Formula XIX:
,CH2CN
DX 'CH2OH
(XIX) e) reacting the compound of the Formula XIX with methanesulfonyl chloride in the presence of thioacetic acid to afford 1-(acetylthiomethyl)-cyclopropaneacetonitrile of the Formula XX:
,CH2CN
IX CH2SAc1 (XX) and f) reacting the compound of the Formula XX with sodium methoxide to afford said compound of the Formula XIV.
7. The process of claim 6, wherein the hydrocarbon solvent is toluene.
8. A process for preparing 2-(2-(3(S)-(3-(2-(7-chloro-2-quinolinyl) ethenyl) phenyl)-3- methane sulfonyloxypropyl) phenyl)-2-propanol, represented by the Formula XXI:
Figure imgf000049_0002
(XXI) said process comprising reacting a diol of the Formula II:
Figure imgf000050_0001
(H) with methane sulfonyl chloride in the presence of a base in a reaction medium that is essentially free of moisture.
9. The process of claim 8, wherein the reaction medium has water content of less than about 0.5%.
10. The process of claim 8, wherein the reaction medium has water content of less than about 0.2%.
11. A process for the preparation of montelukast of the Formula I:
Figure imgf000050_0002
(I) said process comprising: a) reacting a diol intermediate of the Formula II:
Figure imgf000050_0003
(H) with methane sulfonyl chloride in the presence of diisopropyl ethyl amine to afford the compound of the formula (XXI):
Figure imgf000051_0001
(XXI) b) reacting the compound of the formula (XXI) with 1- (mercaptomethyl)cyclopropane acetonitrile to afford the compound of the formula (XXII):
Figure imgf000051_0002
(XXII); c) converting said the compound of the formula (XXII) into a free acid of montelukast of the formula (I).
12. The process of claim 11 , further comprising reacting said free acid of montelukast produced in said step c) with a salt-forming amine to produce an amine salt of montelukast.
13. The process of claim 12, further comprising converting said amine salt of montelukast into a sodium salt of montelukast.
14. The process of claim 12, further comprising purifying said amine salt of montelukast by recrystallization.
15. The process of claim 12, wherein said salt-forming amine is dicyclohexylamine.
16. The process of claim 12, wherein said salt-forming amine is tertiary butyl amine.
17. The process of claim 15, wherein the dicyclohexylamine salt of montelukast is isolated from acetone.
18. The process of claim 16, wherein the tertiary butyl amine salt of montelukast is isolated from acetone.
19. A process for the purification of dicyclohexylamine salt of montelukast, said process comprising: a) providing a solution of dicyclohexylamine salt of montelukast in a combination of an alcoholic solvent and a nitrile solvent; b) cooling said solution thereby causing a solid dicyclohexylamine salt of montelukast to separate from said solution; c) isolating said separated solid.
20. The process of claim 19, wherein the alcoholic solvent is isopropyl alcohol, and the nitrile solvent is acetonitrile.
PCT/US2007/083756 2006-11-06 2007-11-06 Preparation of montelukast and its salts WO2008058118A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07844907A EP2094665A4 (en) 2006-11-06 2007-11-06 Preparation of montelukast and its salts

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
IN2042CH2006 2006-11-06
IN2042/CHE/2006 2006-11-06
IN142/CHE/2007 2007-01-22
IN142CH2007 2007-01-22
US89021507P 2007-02-16 2007-02-16
US60/890,215 2007-02-16
US91486207P 2007-04-30 2007-04-30
US60/914,862 2007-04-30

Publications (2)

Publication Number Publication Date
WO2008058118A2 true WO2008058118A2 (en) 2008-05-15
WO2008058118A3 WO2008058118A3 (en) 2008-07-10

Family

ID=39365306

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/083756 WO2008058118A2 (en) 2006-11-06 2007-11-06 Preparation of montelukast and its salts

Country Status (2)

Country Link
EP (1) EP2094665A4 (en)
WO (1) WO2008058118A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008035379A2 (en) * 2006-09-19 2008-03-27 Aptuit Laurus Private Limited Process for and intermediates of leukotriene antagonists
US7812168B2 (en) 2005-07-05 2010-10-12 Teva Pharmaceutical Industries Ltd. Purification of montelukast
WO2011121091A1 (en) 2010-03-31 2011-10-06 Krka, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
CN102702097A (en) * 2012-05-16 2012-10-03 浙江大学 Preparation method of montelukast sodium intermediate
CN103288695A (en) * 2013-06-18 2013-09-11 陈书峰 Preparation method of 1-mercaptomethylcyclopropyl acetic acid
CN103554016A (en) * 2013-08-23 2014-02-05 南通正达农化有限公司 Processing technology of non-hormonal anti-inflammatory drug intermediate
CN103554017A (en) * 2013-10-25 2014-02-05 河北序能生物技术有限公司 Preparation method of montelukast chiral intermediate
CN104109122A (en) * 2013-04-16 2014-10-22 浙江奥翔药业有限公司 Intermediate compound for synthesizing montelukast, and preparation method thereof
CN104592110A (en) * 2015-01-26 2015-05-06 中山奕安泰医药科技有限公司 Synthesis process of 2-[[3-(S)-[3-[2-(7-chloro-2-quinolyl) ethenyl] phenyl]-3-hydroxypropyl] methyl benzoate
US9717684B2 (en) 2014-04-25 2017-08-01 R.P. Scherer Technologies, Llc Stable montelukast solution
CN109020830A (en) * 2018-08-29 2018-12-18 广州康瑞泰药业有限公司 A kind of methylol cyclopropyl acetonitrile derivative and its methods for making and using same
CN114702416A (en) * 2022-03-30 2022-07-05 法姆瑞斯医药科技(北京)有限公司 Method for efficiently preparing montelukast sodium side chain intermediate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
TW448160B (en) * 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
US5869673A (en) * 1997-02-28 1999-02-09 Merck & Co., Inc. Process for 3-(2-(7-chloro-2-quinolinyl)ethenyl) - benzaldehyde
DE19963115B4 (en) * 1999-12-24 2009-04-09 Evonik Degussa Gmbh Process for the preparation of cyclopropane-1,1-dicarboxylic acid diesters
US7189853B2 (en) * 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts
WO2006021974A1 (en) * 2004-08-23 2006-03-02 Morepen Laboratories Limited A process for synthesizing diol (viii)-an intermediate of montelukast sodium

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2094665A4 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812168B2 (en) 2005-07-05 2010-10-12 Teva Pharmaceutical Industries Ltd. Purification of montelukast
WO2008035379A3 (en) * 2006-09-19 2010-02-18 Aptuit Laurus Private Limited Process for and intermediates of leukotriene antagonists
WO2008035379A2 (en) * 2006-09-19 2008-03-27 Aptuit Laurus Private Limited Process for and intermediates of leukotriene antagonists
WO2011121091A1 (en) 2010-03-31 2011-10-06 Krka, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
CN102702097A (en) * 2012-05-16 2012-10-03 浙江大学 Preparation method of montelukast sodium intermediate
CN104109122B (en) * 2013-04-16 2017-03-29 浙江奥翔药业股份有限公司 For synthesizing midbody compound of montelukast and preparation method thereof
CN104109122A (en) * 2013-04-16 2014-10-22 浙江奥翔药业有限公司 Intermediate compound for synthesizing montelukast, and preparation method thereof
CN103288695B (en) * 2013-06-18 2016-01-13 成都迈斯克医药科技有限公司 The preparation method of 1-thiopurine methyltransferase cyclopropaneacetic acid
CN103288695A (en) * 2013-06-18 2013-09-11 陈书峰 Preparation method of 1-mercaptomethylcyclopropyl acetic acid
CN103554016A (en) * 2013-08-23 2014-02-05 南通正达农化有限公司 Processing technology of non-hormonal anti-inflammatory drug intermediate
CN103554017A (en) * 2013-10-25 2014-02-05 河北序能生物技术有限公司 Preparation method of montelukast chiral intermediate
US9717684B2 (en) 2014-04-25 2017-08-01 R.P. Scherer Technologies, Llc Stable montelukast solution
CN104592110A (en) * 2015-01-26 2015-05-06 中山奕安泰医药科技有限公司 Synthesis process of 2-[[3-(S)-[3-[2-(7-chloro-2-quinolyl) ethenyl] phenyl]-3-hydroxypropyl] methyl benzoate
CN109020830A (en) * 2018-08-29 2018-12-18 广州康瑞泰药业有限公司 A kind of methylol cyclopropyl acetonitrile derivative and its methods for making and using same
CN114702416A (en) * 2022-03-30 2022-07-05 法姆瑞斯医药科技(北京)有限公司 Method for efficiently preparing montelukast sodium side chain intermediate

Also Published As

Publication number Publication date
EP2094665A4 (en) 2010-11-24
WO2008058118A3 (en) 2008-07-10
EP2094665A2 (en) 2009-09-02

Similar Documents

Publication Publication Date Title
EP2094665A2 (en) Preparation of montelukast and its salts
US7528254B2 (en) Process for preparing montelukast and salts thereof
EP1812394B1 (en) Process for the preparation of montelukast and its salts
MXPA06012220A (en) Processes for preparing montelukast sodium.
KR100774088B1 (en) Method of preparing montelukast and intermediates used therein
US20090247759A1 (en) Purification process of Montelukast and its Amine Salts
US20090326232A1 (en) Process for the Preparation of Leukotriene Receptor Antagonist (Montelukast Sodium)
EP2265586A2 (en) Preparation of montelukast and its salts
US8399675B2 (en) Compounds and preparation for montelukast sodium
WO2006064269A2 (en) Salts of leukotriene antagonist montelukast
CN101490005B (en) Process for the purification of Montelukast
US20090182148A1 (en) Process for the manufacture of montelukast sodium
US9487487B2 (en) Process for preparation of montelukast sodium
WO2017122139A1 (en) An improved process for the preparation of pirfenidone
US20080146809A1 (en) Process for the Preparation of Novel Amorphous Montelukast Sodium
US8163924B2 (en) Process for preparing a leukotriene antagonist and an intermediate thereof
WO2008087628A1 (en) Process for preparing montelukast sodium containing controlled levels of impurities
WO2014118796A1 (en) An in-situ process for the preparation of highly pure montelukast sodium
JP6059157B2 (en) Montelukast Intermediate Camphorsulfonate
WO2011004298A1 (en) Montelukast hexamethylenediamine salt and its use for the preparation of montelukast sodium
EP2287154A1 (en) Efficient synthesis for the preparation of montelukast

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07844907

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2532/CHENP/2009

Country of ref document: IN

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007844907

Country of ref document: EP